



# Molecular mimicry of the receptor-binding domain of the SARS-CoV-2 spike protein: from the interaction of spike-specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin

A. V. Sokolov · I. N. Isakova-Sivak · D. A. Mezhenkaya · V. A. Kostevich · N. P. Gorbunov · A. Yu. Elizarova · V. A. Matyushenko · Yu. M. Berson · N. A. Grudinina · N. N. Kolmakov · Y. A. Zabrodskaya · A. S. Komlev · I. V. Semak · A. I. Budevich · L. G. Rudenko · V. B. Vasilyev

Received: 4 September 2022 / Accepted: 21 October 2022 / Published online: 5 November 2022  
© The Author(s), under exclusive licence to Springer Nature B.V. 2022

**Abstract** The pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection involves dysregulations of iron metabolism, and although the mechanism of this pathology is not yet fully understood, correction of iron metabolism pathways seems a promising pharmacological target. The previously observed effect of inhibiting SARS-CoV-2 infection by ferristatin II, an inducer of transferrin receptor 1 (TfR1) degradation, prompted the study of competition between Spike protein and TfR1 ligands, especially lactoferrin (Lf) and transferrin (Tf). We hypothesized molecular mimicry of Spike protein as cross-reactivity of Spike-specific antibodies with Tf and Lf. Thus, strong positive correlations ( $R^2 > 0.95$ ) were found between the level of Spike-specific IgG antibodies present in serum samples of

COVID-19-recovered and Sputnik V-vaccinated individuals and their Tf-binding activity assayed with peroxidase-labeled anti-Tf. In addition, we observed cross-reactivity of Lf-specific murine monoclonal antibody (mAb) towards the SARS-CoV-2 Spike protein. On the other hand, the interaction of mAbs produced to the receptor-binding domain (RBD) of the Spike protein with recombinant RBD protein was disrupted by Tf, Lf, soluble TfR1, anti-TfR1 aptamer, as well as by peptides RGD and GHAIYPRH. Furthermore, direct interaction of RBD protein with Lf, but not Tf, was observed, with affinity of binding estimated by  $K_D$  to be 23 nM and 16 nM for apo-Lf and holo-Lf, respectively. Treatment of Vero E6 cells with apo-Lf and holo-Lf (1–4 mg/mL) significantly inhibited SARS-CoV-2 replication of both Wuhan and Delta lineages. Protective effects of Lf on different arms of SARS-CoV-2-induced pathogenesis and

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s10534-022-00458-6>.

A. V. Sokolov (✉) · I. N. Isakova-Sivak · D. A. Mezhenkaya · V. A. Kostevich · N. P. Gorbunov · A. Y. Elizarova · V. A. Matyushenko · Yu. M. Berson · N. A. Grudinina · N. N. Kolmakov · A. S. Komlev · L. G. Rudenko · V. B. Vasilyev  
Institute of Experimental Medicine, Academica Pavlova Str. 12, St. Petersburg 197376, Russia  
e-mail: [biochemsokolov@gmail.com](mailto:biochemsokolov@gmail.com)

Y. A. Zabrodskaya  
Smorodintsev Research Institute of Influenza,  
Russian Ministry of Health, Prof. Popova Str. 15/17,  
St. Petersburg 197376, Russia

Y. A. Zabrodskaya  
Peter the Great Saint Petersburg Polytechnic University,  
29 Ulitsa Polytechnicheskaya, 194064 Saint Petersburg,  
Russia

I. V. Semak  
Department of Biochemistry, Faculty of Biology,  
Belarusian State University, Nezavisimisty Ave. 4,  
220030 Minsk, Belarus

A. I. Budevich  
Scientific and Practical Center of the National Academy  
of Sciences of Belarus for Animal Breeding, 11 Frunze  
Str., 222160 Zhodino, Belarus

possible consequences of cross-reactivity of Spike-specific antibodies are discussed.

**Keywords** Lactoferrin · Transferrin · Transferrin receptor · Molecular mimicry · Antibody · Severe acute respiratory syndrome coronavirus 2

## Introduction

Pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in late 2019 and so far claimed the lives of more than 6 million people. Today coronavirus disease 2019 (COVID-19) remains a serious public health problem (Aleem et al. 2022). Poor understanding of molecular mechanisms of infection and its complications, as well as the lack of remedies against SARS-CoV-2 with proven efficacy requires that research on this virus be continued. The studies on the design of SARS-CoV-2 antivirals are complicated by the presence of multiple receptors on a host cell surface that the virus uses to enter the cell, such as angiotensin-converting enzyme 2 (ACE2), neuropilin-1, CD147, tyrosine-protein kinase receptor UFO (AXL) and other co-receptors (Scialo et al. 2020; Shang et al. 2020; Zhang et al. 2020; Wang et al. 2020a, 2021; Wei et al. 2020; Daly et al. 2020; Cantuti-Castelvetri et al. 2020; Jackson et al. 2022). Dysregulation of iron metabolism in SARS-CoV-2-infected patients, which is associated with onset of hypoxia, inflammation, and the response to oxidative stress has been widely reviewed (Cavezzi et al. 2022; Naidu et al. 2022; Kronstein-Wiedemann et al. 2022; Suriawinata and Mehta 2022). In this regard, the therapeutic potential of lactoferrin (Lf), a cationic homologue of serum transferrin (Tf), has been widely discussed as a regulator of inflammation, iron metabolism, tolerance to hypoxia and oxidative stress. Suriawinata and Mehta (2022) first discussed SARS-CoV-2-related dysregulations of iron metabolism in view of the transferrin receptor (TfR1) involvement in the infection (Tang et al. 2020a, b). Interestingly, the severity of COVID-19 is shadowed by the level of ferritin (Suriawinata and Mehta 2022), the heavy-chain form of which also interacts with TfR1. However, the binding site for ferritin is different from that for Tf (Sakamoto et al. 2015).

Interaction of TfR1 and ACE2 with Spike protein, excessive susceptibility to SARS-CoV-2 of mice

transgenic for human *TfR1*, and protective effects of antibodies against TfR1 that reduce the severity of pathological changes in the lungs of infected mice have been demonstrated (Tang et al. 2020a, b). We pursued this area of research by testing the effect of TfR1 degradation on infection of Vero cells by SARS-CoV-2. Thus, we observed dose-dependent inhibition of SARS-CoV-2 replication ( $IC_{50} \sim 6\text{--}40 \mu\text{M}$ ), as well as abrogated endocytosis of the receptor-binding domain (RBD) of Spike protein after treatment of cell culture with ferristatin II (Sokolov et al. 2022a, b). This compound induced degradation of TfR1 (Byrne et al. 2013), and was initially discovered in screening small-size inhibitors of iron influx into cancer cells (Brown et al. 2004). Byrne and colleagues (2013) hypothesized that ferristatin II releases human hemochromatosis protein (HFE) from its complex with TfR1 (Lebron et al. 1999), which results in TfR1 degradation and up-regulation of hepcidin. Although ferristatin II (also known as direct black 38, Chlorazol black E, C.I. 30,235) was non-toxic for cultured Vero cells and effectively altered iron metabolism in mice and rats, it is degraded to benzidine metabolites and cannot be used directly in humans (Dewan et al. 1988; Römer et al. 2014; Alkhateeb et al. 2015). Nevertheless, inhibiting SARS-CoV-2 entry by targeting TfR1 on the host cells, rather than the viral mutation-prone Spike protein, seems to be a promising therapeutic strategy.

The key role of TfR1 in cancer cell growth and TfR1-mediated penetration through the blood–brain barrier prompted the studies of several “anti-cancer” and “brain-directed” TfR1-binding molecules and their derivatives, including Tf and Lf conjugates, synthetic peptides, i.e. HAIYPRH (also known as T7), aptamers, and monoclonal antibodies (mAbs) (Luck and Mason 2013; Mahidhara et al. 2015; Liang et al. 2018; Ayo et al. 2021; Candelaria et al. 2021; Zhang et al. 2022). RGD motif (integrin-binding motif) of TfR1 is involved in binding of Tf and Lf, as was demonstrated in structural studies of the complex formed by Tf and TfR1 (Dubljevic et al. 1999; Xu et al. 2005; Sakamoto et al. 2006). A mutation (R646H/G647A) in RGD-motif of TfR1 reduced cellular uptake of holo-Tf, but had no effect on heavy-chain ferritin uptake (Sakamoto et al. 2015). Noteworthy, the RBD of Spike protein of all SARS-CoV-2 lineages also contains RGD motif, whereas it is absent in previous human coronavirus variants

(Dakal 2021; Makowski et al. 2021; Othman et al. 2022; Norris et al. 2022). Moreover, the interaction of Spike protein with bovine Lf has been reported in at least three studies (Campione et al. 2021; Miotto et al. 2021; Cutone et al. 2022). Several studies demonstrated protective effects of Lf (recombinant and milk-derived) against SARS-CoV-2 infection in vitro (Campione et al. 2021; Prieto-Fernández et al. 2021; Salaris et al. 2021; Mirabelli et al. 2021; Hu et al. 2021; Lai et al. 2022; Worting et al. 2022; Cutone et al. 2022). Different mechanisms of antiviral effect of Lf have been proposed, but not all papers contain information on the degree of iron saturation of Lf. In neutrophils granules, milk and other exocrine secretions, Lf is present predominantly in the apo-form (Masson et al. 1966; Britigan et al. 1994). The affinity of Lf to Fe(III) is much less affected by a decrease in pH, as compared with Tf, which is usually attributed to the noticeable bacteriostatic effect of apo-Lf (Brock 1980; Baker and Baker 2004). In the last two decades the anti-anaemic effect of Lf and its involvement in iron metabolism, especially in regulation of IL-6 and hepcidin effects, have been extensively studied (Cutone et al. 2014; Rosa et al. 2017; Lepanto et al. 2019; Artym et al. 2021). Iron-saturation of Lf affects the expression of *TfR1* gene, i.e. apo-form of Lf up-regulates TfR1 via hypoxia-inducible factor (HIF) pathway; in contrast, holo-Lf down-regulates the expression of *TfR1* (Zhang et al. 2021). It is worth noting that Tf and Lf also interact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) which mediates Tf uptake and a rapid response to hypoxia (Kumar et al. 2012; Rawat et al. 2012; Malhotra et al. 2019). Other recent reviews on Lf structure and functions include its interactions with intelectin-1 (omentin-1), CD14, chemokine receptor 4 (CXCR4), and low-density lipoprotein receptor-related protein (LRP) in cellular receptors list, but interaction of Lf with TfR1 received little attention (Li and Guo 2021; Artym et al. 2021; Suzuki et al. 2005; Lepanto et al. 2019; Elzoghby et al. 2020; Godínez-Chaparro et al. 2021) or was fully neglected (Kawakawi et al. 1990; Mahidhara et al. 2015; Kell et al. 2020; Bartolomé et al. 2022). Interestingly, TfR1 is regarded as cellular receptor of Lf in a recent survey of its antiviral activity, and the corresponding scheme is presented (Ward et al. 2022). However, participation of TfR1 in interaction with SARS-CoV-2 is not mentioned, although the paper largely deals with an impact of

viral infections on iron metabolism and describes the mechanisms of antiviral effect of Lf against SARS-CoV-2, in particular of the protein from cow milk (Ward et al. 2022). Taking into account the homology of Tf and Lf and their interaction with RGD-motif of TfR1, our study was focused on Tf and Lf, despite that the list of natural ligands of TfR1 also includes HFE, heavy-chain ferritin, haem-albumin (Jennifer et al. 2020) etc. Considering TfR1-HFE-mediated up-regulation of hepcidin and high levels of hepcidin and ferritin in serum samples obtained from severe COVID-19-infected patients (Zhou et al. 2020), we cannot exclude that COVID-19 infection alters the interaction of TfR1 with HFE and/or heavy-chain ferritin.

We hypothesized a molecular mimicry of SARS-CoV-2 Spike protein with Tf and Lf. To test this hypothesis, we examined the cross-reactivity of antibodies against Spike protein, Tf and Lf; the competition between Spike protein and synthetic TfR1 ligands, as well as Tf and Lf; and finally, the antiviral effects of apo- and holo-Lf.

## Materials and methods

### Materials

The following reagents were used in the study: anti-TfR1 polyclonal rabbit antibody (ab84036, Abcam, UK); bovine serum albumin (BSA), dimethyl sulfoxide (DMSO), horseradish peroxidase (HRP) with  $RZ > 3.0$  (Amresco, USA); recombinant SARS-CoV-2 Spike protein (1-1208 a.a., trimer, AtaGenix Laboratories, Wuhan, China); Bio-Gel A-1.5 m, Chelex-100, skimmed milk protein (blotting grade), HRP-labeled antibody against mouse IgG, HRP-labeled antibody against human IgG, HRP-labeled antibody against rabbit IgG, Tween 20, UNOsphere Q, UNOsphere S, (Bio-Rad, USA); acrylamide, ammonium persulfate, glycerol, glycine, mercaptoethanol, N,N'-methylenebis-acrylamide, N,N,N'-tetramethylethylene diamine, Tris, NaCl, KCl,  $(\text{NH}_4)_2\text{SO}_4$ ,  $\text{H}_3\text{BO}_3$  (Helicon, Russia); HCl and  $\text{H}_2\text{SO}_4$  (Lenreactiv, Russia); N-hydroxysuccinimide ester of 5-TAMRA (Lumiprobe, Russia); biotinamidohexanoic acid N-hydroxysuccinimide, biotin hydrazide, CM-Sepharose, Coomassie R-250, phenylmethylsulfonyl fluoride SDS, Sephadex G-75 Superfine, soybean trypsin

inhibitor (STI), 3,3',5,5'-tetramethylbenzidine, Triton X-100, trypsin from bovine pancreas (Sigma Aldrich, USA), DEAE-Toyopearl 650-M (Toyosoda, Japan).

A recombinant protein corresponding to the receptor-binding domain (RBD) of SARS-CoV-2 S protein (Prokofyev et al. 2021) was expressed in eucaryotic cells by BIOCAD JSC (St. Petersburg, Russia). Aptamer against TfR1 Cy5-ACTCATAGGGTTAGG GGCTGCTGGCCAGATACTCAGATGGTAGGG TTACTATGAGC (Zhang et al. 2022) was synthesized by the company “Evrogen” (Russia). Peptides RGD and GHAIYPRH were synthesized by solid-phase synthesis on a 2-chlorotriyl chloride resin according to the Fmoc/tBu strategy using the carbodiimide method starting from the C-terminus. The peptides were purified from side products by RP-HPLC. To confirm the expected molecular mass the products obtained were analyzed by mass spectrometry.

Solutions for chromatography and surface plasmon resonance assay were prepared using apyrogenic deionized water with specific resistance  $18.2 \text{ M}\Omega \times \text{cm}$ . Following buffers were used: 150 mM NaCl, 10 mM Na-borate buffer, pH 8.3—BBS; 150 mM NaCl, 10 mM Na-phosphate buffer, pH 7.4—PBS; BBS and PBS, supplemented by 0,05% Tween 20—BBS-T, PBS-T; 150 mM NaCl, 10 mM Hepes–NaOH, pH 7.4 (HBS).

### Viruses

Two strains of SARS-CoV-2 were obtained from the repository of Smorodintsev Research Institute of Influenza (Saint-Petersburg, Russia): hCoV-19/St\_Petersburg-3524S/2020 (lineage B.1, Wuhan) and hCoV-19/Russia/SPE-R11-32759 V/2021 (lineage B.1.617.2, Delta). Virus stocks were generated by infecting Vero-E6 cells at a multiplicity of infection (MOI) 0.01 using DMEM supplemented with 2% FBS, 10 mM HEPES and  $1 \times$  antibiotic–antimycotic (all from Capricorn, Ebsdorfer-grund, Germany). After incubation for 72 h, cell supernatants were harvested, subjected to low-speed centrifugation to remove cell debris and stored in single-use aliquots at  $-70 \text{ }^\circ\text{C}$ . Viral titers were determined by infecting 96-well plates seeded with Vero E6 cells, as described in (Amanat et al. 2020), and expressed in  $\log_{10}\text{TCID}_{50}/\text{mL}$ .

### Isolation and purification of proteins

Recombinant human apo-Lf purified from the milk of transgenic goats was obtained at the Belarusian State University and RUE «Scientific and Practical Centre for Animal Production of the National Academy of Sciences of Belarus». The product is officially branded “CAPRABEL™” and contains about 90% of the iron-free form of Lf (Semak et al. 2019). Tf was isolated from human blood plasma by ion-exchange chromatography on DEAE-Toyopearl, UNOsphere S and gel filtration on Sephadex G-75 Superfine (Sokolov et al. 2017). Apo-form of Tf was obtained by adding 2 mM ascorbic acid to 8 mg/mL Tf in 100 mM Na-acetate buffer, pH 5.5, the protein was immediately dialyzed against buffer containing 100 mM  $\text{Na}_2\text{HPO}_4$  and 50 mM citric acid (pH 4.8), followed by the buffer replacement with HBS using centrifuge concentrators (Vivaspin 20, cut off 30 kDa). Holo-forms of Lf and Tf were obtained by adding 0.8 mM Fe(III) (10 mM stock solution of  $\text{NH}_4\text{Fe}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$  in 100 mM Na-acetate buffer, pH 5.5) to 8 mg/mL of proteins in 200 mM Na-phosphate-citrate buffer (pH 8.0), followed by dialysis against the same buffer and filtration on a column with Chelex-100 equilibrated with HBS.

To obtain an affinity sorbent for TfR1 purification we used holo-Tf immobilized on Sepharose 6B activated by BrCN (about 5 mg holo-Tf per 1 mL of wet gel). TfR1 was purified from human placenta with small modifications of earlier protocols (Seligman and Allen 1987; Turkewitz et al. 1988; Kanevsky et al. 1997)—see Supplementary data, section S1. Soluble form of TfR (sTfR) was obtained by limited proteolysis of TfR with trypsin and by ion-exchange chromatography—see Supplementary data, section S2. Identification of TfR and sTfR by MALDI-TOF-tryptic fingerprint was performed—see Supplementary data, section S3, Figure S1.

### Obtaining rabbit polyclonal antibodies against Tf and murine mAbs against human Lf and SARS-CoV-2 spike protein

To obtain polyclonal antibodies against Tf, rabbits were immunized with 300  $\mu\text{g}$  of purified human holo-Tf, which was additionally cleared from admixtures by disc-electrophoresis in detergent-free polyacrylamide gel (see “[Electrophoresis and western blotting](#)”)

with single-well comb for sample loading. After electrophoresis the narrow red band corresponding to holo-Tf was cut out of gel. Half of the gel was homogenized with equal volume of PBS and emulsion obtained was injected intracutaneously with 1/10 volume of Freund's adjuvant (complete and incomplete for the first and the second injection, respectively). The second half of the gel was frozen awaiting the second injection. On the 8th, 12th, and 16th day after the second injection blood was collected, and separated serum was used for isolating IgG by ammonium sulphate fractionation and affinity chromatography on Tf-Sepharose. Purified antibodies were tested for specific reaction with human Tf in samples of human serum and plasma (Western-blotting and ELISA Enzyme-linked immunosorbent assay (ELISA)).

For obtaining mAbs, the hybridoma technology was used (Pandey et al. 2010). Briefly, 20 µg of Lf or Spike protein with complete Freund's adjuvant per mouse (BALB/c) were used for the first immunization, and after 1 month 5 µg for the second. Then, on the 4th day, abdominal lymph nodes were removed and lymphocytes were mixed with SP2/0-AG14 cells (2:1). After hybridization with polyethylene glycol (1500) cells were seeded in 96-well cultural plates with one-day peritoneal macrophages. Hybrids were selected in RPMI-1640 medium supplemented with 10% fetal bovine serum and HAT-reagent. Enzyme-linked immunosorbent assay (ELISA) with Lf or Spike protein, and BSA as negative control were used for primary selection of clones ("ELISA"). Selected clones (4 for Lf and 6 for Spike protein) were sub-cloned, and individual clones were cultivated for injecting into mice (2 million cells per animal) and obtaining ascites. After 2 weeks ascitic fluids collected from the mice were used for purification of antibodies. Saturation by ammonium sulphate and affinity chromatography on a resin with immobilized Protein A allowed to obtain no less than 96% pure IgGs according to SDS–polyacrylamide gel electrophoresis (SDS-PAGE) analysis (see "Electrophoresis and western blotting"). mAbs against Lf were labeled according to the code of a well (3E11 and 3H5), while mAbs against Spike protein were designated as S1–S6. Selection of mAbs reacting with RBD of Spike protein was performed by ELISA ("ELISA").

### Labeling of proteins

Spike protein was labeled by linking biotin to primary amino groups (Spike-A-Bi) using biotinamidohexanoic acid N-hydroxysuccinimide ester and to carbohydrate moiety (Spike-C-Bi) using sodium periodate oxidation of carbohydrates and biotin hydrazide. Labeling of proteins (IgG, Lf and Tf) with HRP was performed by sodium periodate oxidation of HRP carbohydrates and conjugation with proteins, followed by reduction of Schiff's bases with NaBH<sub>4</sub>. Obtained HRP-labeled proteins were stored at – 20 °C in 50% glycerol.

Labeling by 5-TAMRA was carried out at +4 °C for 12 h by adding 5 mM solution of N-hydroxysuccinimide ester of 5-TAMRA in DMSO to 30 µM apo-Lf, apo-Tf, holo-Lf, holo-Tf, or RBD solutions in 200 mM NaHCO<sub>3</sub>, keeping the ratio 5-TAMRA:protein = 8:1 (mol/mol). After removal of excessive dye, the degree of labeling was estimated by the ratio of A<sub>541</sub> to A<sub>280</sub>, which ranged from 3.2 to 3.8 mol TAMRA per mol protein.

### Recruiting participants and collecting blood samples

55 serum samples were collected from 53 COVID-19-recovered patients aged 21 to 84 years who participated in the study of SARS-CoV-2-specific humoral and T-cell responses (Matyushenko et al. 2021). The study was approved by the Ethics Committee of the Institute of Experimental Medicine (protocol No 2/20 dated 7 April 2020). Serum was sampled 1–12 months past recovery. A cohort of 24 COVID-19 naïve participants (aged 24 to 91 years) was used as a control group. A cohort of 16 Sputnik V-vaccinated individuals (aged 27–74 years) was used as a positive control group. Serum was sampled 1–4 months past vaccination. Serum samples were collected from individuals to assay anti-Spike and anti-RBD IgG, and Tf-binding capacity of these IgGs ("ELISA"). IgGs from representative samples of each cohort were purified by Protein A affinity chromatography for further Tf- and Lf-binding analyzes.



## Analytical methods

### Spectrophotometry

Optical spectra were registered on SF-2000-02 spectrophotometer («OKB-Spectr», Russia). Concentrations of purified apo-Lf, apo-Tf, and Fe(III)-saturated holo-forms were measured using the following extinction coefficients: apo-form Lf— $\epsilon_{280}=87,360 \text{ M}^{-1} \text{ cm}^{-1}$ , apo-form Tf— $\epsilon_{280}=89,155 \text{ M}^{-1} \text{ cm}^{-1}$ , holo-form Lf— $\epsilon_{465}=4267 \text{ M}^{-1} \text{ cm}^{-1}$ , holo-form Tf— $\epsilon_{465}=4446 \text{ M}^{-1} \text{ cm}^{-1}$  (Masson 1970).

### ELISA

Specific conditions of different variants of direct and competitive ELISA performed are summarized in Table 1. In all cases, polystyrene 96-well plates with high-binding capacity were incubated with 100  $\mu\text{L}$  of immobilized protein (antigen or primary antibody against analyte detected in the assay) in BBS at 4 °C in a humidified chamber. Other reagents added into the wells were incubated in a thermoshaker (BioSan, 350 rpm, 37 °C, commonly for 1 h). Prior to the addition of the next reagent, the plates were washed with BBS-T or PBS-T in an automatic plate washer (PW-40, Bio-Rad). To prevent non-specific binding, 100  $\mu\text{L}$  of a blocking reagent were added: 3% BSA or 3% skimmed milk protein in BBS-T or PBS-T (incubation for 1 h). Then, the analyte-containing samples (interacting with immobilized protein alone or with a competitor) were added. Next, either a chromogenic mixture (in case of competitive assay of HRP-labeled analyte) or HRP-labeled streptavidin (in case of biotin-labeled analyte) or HRP-labeled specific antibody was added. For HRP-labeled reagents, 100  $\mu\text{L}$  of a chromogenic mixture containing 0.5 mM 3,3',5,5'-tetramethylbenzidine and 2 mM hydrogen peroxide in 50 mM Na-acetate buffer (pH 5.5) were added. After development of the blue color (5–30 min), the reaction was terminated by adding 50  $\mu\text{L}$  of 1 M  $\text{H}_2\text{SO}_4$ . Absorbance at 450 nm was registered in a microplate reader CLARIOstar (BMG Labtech, Germany).

*ELISA of mouse IgG against Lf and spike protein in culture medium for selection of hybridomas* For

selection of hybridomas (“Obtaining rabbit polyclonal antibodies against Tf and murine mAbs against human Lf and SARS-CoV-2 spike protein”), secretion of IgGs against Lf or Spike protein in culture medium was directly assayed. The level of mAbs against coated Lf or Spike protein was measured using HRP-labeled anti-mouse IgG (Table 1). BSA was also used as a blocking agent and coating protein (without antigens) for negative selection of hybridomas. mAbs raised against Spike protein and also capable of reacting with RBD were selected in a direct assay with HRP-labeled anti-mouse IgG of their binding with RBD or Spike protein on solid phase.

*ELISA of IgGs against spike protein and RBD, and of binding human Tf with IgGs in serum samples* Each sample of serum was used in triplicate in four types of assays. Spike protein or RBD was immobilized on duplicate plates, followed by incubation with serum samples diluted 1:25. One of these plates was stained for IgGs (HRP-labeled human anti-IgG), while the other plate was stained for reaction of IgG with Tf (HRP-labeled anti-Tf) (see Table 1). The repeats of ELISA might vary due to numerous factors, starting with the time interval before the reaction is stopped and the fluctuations of the immobilized protein, and ending with the degree of dilution of samples and stock solutions of HRP-labeled reagents.  $A_{450}$  was repeatedly measured in 93 samples corresponding to the number of patients under study. For the control of intra-assay variations, each series of measurements included two duplicate samples obtained from patients recovered from COVID-19 and a duplicate sample from naïve donor. Those samples served as the highest, the medium, and the lowest point in the distribution of data. Upon normalization of the data obtained, these three duplicate samples were excluded from the overall results. The final IgG antibody level was defined as the  $A_{450}$  value multiplied by serum dilution ( $\times 25$ ).

*ELISA of human Tf* Human Tf was assayed in sandwich ELISA with polyclonal rabbit anti-Tf on solid phase (Table 1). HRP-labeled polyclonal antibodies were applied after incubation of tested samples in serial dilutions and of Tf standards (1–4000 ng/mL).

*ELISA of binding human Lf with IgGs and Tf obtained from serum samples* Binding of human Lf was

**Table 1** The specific conditions and principles of ELISA variants performed in study

Detected analyte or its binding (section)	Principle of ELISA	Protein on solid phase	Blocking agent (B) and solution for plate washing (W)	Samples with analyte, time of incubation	Reagent for analyte detection, time of incubation
“ELISA of mouse IgG against Lf and spike protein in culture medium for selection of hybridomas” Mouse IgG against Lf or Spike protein	Direct assay of IgG against Lf or Spike by HRP-labeled anti-mouse IgG	5 µg/mL Lf or 0.5 µg/mL Spike protein in BBS	B—3% BSA in BBS-T; W—BBS-T	Culture medium samples (1:3 or more diluted) in W, 1 h	Anti-mouse IgG-HRP (1:4000) in B, 1 h
“ELISA of mouse IgG against Lf and spike protein in culture medium for selection of hybridomas” mAbs against Spike protein binding RBD	Direct assay of IgG against RBD (or Spike protein) by HRP-labeled anti-mouse IgG	1 µg/mL RBD or 0.5 µg/mL Spike protein or in BBS	B—3% skimmed milk protein in PBS-T; W—BBS-T	50–200 ng/mL of tested mAbs in B, 1 h	Anti-mouse IgG-HRP (1:4000) in B, 1 h
“ELISA of IgGs against spike protein and RBD, and of binding human Tf with IgGs in serum samples” Human IgG against Spike protein and RBD	Direct assay of IgG against Spike or RBD by HRP-labeled anti-human IgG	0.5 µg/mL Spike protein or 1 µg/mL RBD in BBS	B—3% skimmed milk protein in PBS-T; W—BBS-T	Serum samples (1:25 or 1:50 dilution) in B, 2 h	Anti-human IgG-HRP (1:4000) in B, 1 h
“ELISA of IgGs against spike protein and RBD, and of binding human Tf with IgGs in serum samples” Tf binding with human IgG against Spike protein and RBD	Direct assay of Tf binding with antibody against Spike protein and RBD by HRP-labeled anti-Tf	0.5 µg/mL Spike protein or 1 µg/mL RBD in BBS	B—3% skimmed milk protein in PBS-T; W—BBS-T	Serum samples (1:25 or 1:50 dilution) in B, 2 h	400 ng/mL of anti-human Tf-HRP in B, 1 h
“ELISA of human Tf” in samples	Direct assay of Tf by HRP-labeled anti-Tf after binding with the same polyclonal anti-Tf on solid phase	5 µg/mL anti-Tf in BBS	B—3% skimmed milk protein in PBS-T; W—BBS-T	Tested samples (from 1:10 to 1:4000 dilutions) or standards of human Tf (0–4000 ng/mL) in B, 2 h	100 ng/mL of anti-human Tf-HRP in B, 1 h
“ELISA of binding human Lf with IgGs and Tf obtained from serum samples” Lf binding with human IgG and purified Tf	Direct assay of Lf binding with antibody isolated from serum samples or purified Tf by HRP-labeled Lf	5 µg/mL IgG or Tf in BBS	B—3% skimmed milk protein in PBS-T; W—BBS-T	200 ng/mL of Lf-HRP in B, 1 h	

**Table 1** (continued)

Detected analyte or its binding (section)	Principle of ELISA	Protein on solid phase	Blocking agent (B) and solution for plate washing (W)	Samples with analyte, time of incubation	Reagent for analyte detection, time of incubation
“ELISA of spike protein binding with Lf and mAbs against Lf” Spike protein binding with Lf and mAbs against Lf	Competitive assay of Lf and biotin-labeled Spike to primary amino groups (Spike-A-Bi) or to carbohydrate moiety (Spike-C-Bi) for binding with mAbs against Lf	5 µg/mL mAbs (clones 3H5 or 3E11) in BBS	B—3% BSA in BBS-T; W—BBS-T	200 ng/mL Spike-A-Bi or 40 ng/mL Spike-C-Bi and 2 mg/mL of Lf in B, 1 h	50 ng/mL HRP-streptavidin in B, 30 min
“ELISA of competitors of anti-spike mAb binding with RBD” Competitors of binding mAb against Spike to RBD	Competitive assay of HRP-labeled mAb against Spike and competitors (sTfR, Tf, Lf, aptamer against TfR1, peptides GHAIYPRH and RGD) for binding with RBD	2 µg/mL RBD in BBS	B—3% skimmed milk protein in PBS-T; W—BBS-T	200 ng/mL HRP-labeled S6 and serial dilutions of 44 nM sTfR, 640 nM Tf or Lf, 500 nM aptamer against TfR1, 21 µM GHAIYPRH or 120 µM RGD, in B, 1 h	

assayed in sandwich ELISA with HRP-labeled Lf and IgGs or Tf on solid phase (Table 1). HRP-labeled Lf was applied after immobilization of IgGs or purified Tf on solid phase (5 mg/mL).

*ELISA of spike protein binding with Lf and mAbs against Lf* Binding of Spike protein with Lf and mAbs against Lf was studied in a competitive assay. Two different mAbs against Lf (3H5 or 3E11) were immobilized on solid phase. Aliquots of Spike protein labeled by biotin to primary amino groups (Spike-A-Bi) or to carbohydrate moiety (Spike-C-Bi) were added to Lf in different concentrations (Table 1). Cooperative binding of biotin-labeled Spike protein with Lf and mAbs against Lf, or its competition with increasing Lf concentrations for binding to mAbs against Lf was detected using HRP-streptavidin conjugate.

*ELISA of competitors of anti-spike mAb binding with RBD* Different ligands of TfR and sTfR were studied as competitors of interaction between mAb against Spike (S6) with RBD immobilized on solid phase. Binding of HRP-labeled mAb against Spike with different concentrations of sTfR (0.7–44 nM), Tf or Lf (10–640 nM), aptamer against TfR1 (50–500 nM), peptides RGD (2–120 µM) and GHAIYPRH (0.33–21 µM) was tested (Table 1). Results of analysis were presented as the dependence of binding on the concentration of a competitor.

#### *Electrophoresis and western blotting*

Proteins and their complexes were resolved under non-denaturing conditions by detergents-free disc-electrophoresis in polyacrylamide gel (disc-PAGE) (David 1964). Molecular weight of proteins and their homogeneity were analyzed by electrophoresis in SDS-containing gel in high-molar Tris buffer (SDS-PAGE) (Fling and Gregerson 1986). Proteins were identified by Western blotting (Anderson et al. 1982). After semi-dry transfer, the nitrocellulose membrane with proteins was kept for 30 min in 3% solution of dried skimmed milk in PBS-T. The membrane was left for 1 h or overnight for incubation with a primary antibody, followed by 2-h incubation with HRP-labeled secondary antibodies (1:1000). Bands that bound secondary antibodies were revealed after incubation of the membrane in the chromogenic solution obtained by mixing 2 ml of methanol containing



6 mg of 4-chloro-1-naphthol with 10 ml of 5 mM H<sub>2</sub>O<sub>2</sub> in PBS.

#### *Surface plasmon resonance assay binding of Lf to RBD*

SPR measurements were carried out at 25 °C using a carboxymethylated-dextran chip (CM5) on dual flowcell Biacore × 100 instrument (GE-Healthcare, Piscataway, NJ, USA). The sensor chip was first activated with an equimolar (0.2 M) mixture of N-ethyl-N-dimethylaminopropylcarbodiimide and N-hydroxy-succinimide and then reacted with a solution of RBD (230 µg/mL) in 10 mM sodium acetate buffer, pH 5.5, injected at a flow rate of 5 µl/min for 12 min. Unreacted carboxymethyl groups on the sensor chip were blocked by 1 M ethanolamine at pH 8.5. Final immobilization levels of 3913 resonance units (RU) were obtained, corresponding to approximately 3.9 ng of bound RBD/mm<sup>2</sup>. Thereafter, increasing concentrations of apo-Lf and holo-Lf (4–256 nM) were injected over the RBD-coated sensor chip at a flow rate of 10 µl/min in 150 mM NaCl, 10 mM HEPES–NaOH, pH 7.5, 0.05% polyoxyethylene sorbitan (HBS-P+). Each run consisted of four steps: (1) buffer injection for 1 min; (2) Lf injection for 1 min; (3) dissociation for 5 min; (4) regeneration for 90 s with HBS-P+, containing 1 M NaCl. The reference flow cell, with no RBD immobilized, was used as a control to evaluate non-specific binding (<2% of R<sub>max</sub>) of Lf to the sensor chip. The resulting control curves were subtracted from the corresponding binding curves recorded at each Lf concentration. The equilibrium dissociation constant, K<sub>D</sub>, of RBD-Lf complex was determined by plotting the steady-state value of RU as a function of Lf concentration, and the data were fitted to the Langmuir equation describing the one-site binding model. Kinetic parameters (k<sub>on</sub>—association rate constant, k<sub>off</sub>—dissociation rate constant, K<sub>D</sub>—equilibrium dissociation constant, and R<sub>max</sub>—A binding capacity of the surface) were calculated using the 1:1 binding model.

#### *Inhibition of SARS-CoV-2 replication by RBD-binding mAb against spike protein*

The virus inhibitory effect of mAb against Spike protein (selected by RBD-binding) was studied in a standard microneutralization assay on Vero-CCL81

cells, as described earlier (Matyushenko et al. 2021). Briefly, two-fold dilutions of antibody were prepared on DMEM/2%FBS medium in sterile U-bottom 96-well plates in a volume of 160 µL. Importantly, tested mAbs against Spike protein were diluted in a human serum sample (final concentration 10 µg/mL) to ensure the presence of human serum proteins which could potentially interfere with mAb binding to the virus. A serum sample from a COVID-19 convalescent patient was used as a positive control, while sera from a COVID-19 naive subject was used as a negative control. Each sample was assessed in duplicates. Fifty microliters of each dilution were transferred to a new 96-well plate and an equal volume of 300 TCID<sub>50</sub> of SARS-CoV-2 was added to each well, followed by 1-h incubation at 37 °C. Then, the virus-antibody mixtures were applied to 96-well culture plates with confluent monolayer of Vero-CCL81 cells, followed by additional incubation for 1 h at 37 °C, 5% CO<sub>2</sub>. After adsorption, the inoculum was removed and the cells were covered with 100 µL of corresponding antibody dilutions. Finally, 50 µL of DMEM/2%FBS was added to each well, and the plates were incubated at 37 °C, 5% CO<sub>2</sub>. Two days later, the plates were fixed with 10% formaldehyde for 24 h at 4 °C, and the plates were subjected to cell-ELISA using polyclonal rabbit antibody specific to SARS-CoV-2 Spike RBD protein (BIOCAD, Saint Petersburg, Russia) as a primary antibody and anti-rabbit IgG HRP-conjugated antibody (Bio-Rad) as a secondary antibody. The plates were developed with 1-Step™ Ultra TMB-ELISA Substrate Solution (Thermo, USA) and the signal was read on xMark Microplate Absorbance Spectrophotometer (Bio-Rad). The MN<sub>50</sub> titers were calculated using four-parametrical non-linear regression analysis as described in (Amanat et al. 2020).

#### *Assessment of antiviral effect of lactoferrin in vitro*

The antiviral effect of Lf was studied as described earlier (Sokolov et al. 2022a), with the exception that Vero E6 cells were used in this test. Briefly, 24-h cell monolayers in 96-well plates were infected with 100 TCID<sub>50</sub> of SARS-CoV-2 per well, for 2 h at 37 °C, 5% CO<sub>2</sub>. After infection, the inoculum with residual virus was removed, followed by the addition of 150 µL of DMEM/2%FBS medium containing various concentrations of apo-Lf and

holo-Lf. Each Lf concentration was tested in triplicate, and appropriate positive and negative controls were included. After incubation for 48 h (for B.1 Wuhan strain) or 72 h (for B.1.617.2 Delta strain), cell supernatants were harvested in 0.2 ml tubes and stored at  $-70\text{ }^{\circ}\text{C}$  until RNA extraction. Biolabmix RU-250 spin column kit (Biolabmix, Novosibirsk, Russia) was used to extract viral RNA from the collected supernatants, as well as from the viral stocks with known infectious titers. Viral load in each sample was determined by quantitative RT-PCR using Evrogen One-Tube RT-PCR SYBR kit (Moscow, Russia) with  $50\times\text{ROX}$  as a reference dye, on Quantstudio 1 Real-Time PCR System (ThermoFisher Scientific, Waltham, MA, USA). The reaction was set up as described in (Wang et al 2020b) using forward primer 5'-CAATGGTTTAAACAGGCACAGG-3' and reverse primer 5'-CTCAAGTGTCTGTGGATCACG-3'. Each RNA sample was tested in duplicate, and the average cycle threshold (Ct) value was used to calculate the virus titer from a standard curve obtained from dilutions of viral RNA with a known titer, using QuantStudio Design and Analysis Software v1.5.1.


## Statistical analysis

Data presented as mean and standard deviation for measurements repeated in triplicates (unless otherwise specified). IgG antibody level presented as median and Q1-Q3, equations of linear and power regressions for antibodies levels were characterized by coefficients of determination ( $R^2$ ). Data of antiviral activity of Lf were analyzed by two-way ANOVA with Tukey's post-hoc multiple analyses test.

## Results

### Analysis of Tf and Lf binding with human IgGs against spike protein and RBD

To test our hypothesis about molecular mimicry between RBD of Spike protein and Tf/Lf, as two homologous host ligands of TfR1, we set up several experiments of Tf or Lf binding with IgGs against Spike protein or its RBD fragment present in serum samples of study participants. First, serum levels of anti-RBD or anti-Spike IgGs were measured by indirect ELISA with corresponding antigens immobilized




**Fig. 1** Distributions of the levels of IgGs antibodies against Spike protein **a** and against RBD **b** in serum samples of naïve, Sputnik V-vaccinated and COVID-19 recovered donors; data presented as median and Q1-Q3; schemes of ELISA presented in inserts

on solid phase (Fig. 1). Then, three variants of ELISA were performed to study the binding of these antibodies with Tf or Lf—Supplementary data (S4, Figures S2, S3, Table S1). Interaction of Lf with RBD and Spike protein, and of Spike with anti-Lf prompted to choose only one mode of ELISA with RBD or Spike protein immobilized on solid phase and IgGs detected by adding HRP-labeled anti-human Tf. We expanded the sample set of naïve, vaccinated and COVID-19-recovered individuals for studying the cross-reactivity of antibodies (“Recruiting participants and collecting blood samples”). Positive linear distributions of RBD- and Spike-specific IgG levels and their cross-reactivity with Tf, as measured by HRP-labeled anti-human Tf, were found with  $R^2$  values close to 1 in vaccinated and COVID-19-recovered groups (Fig. 2).

Fractionation of serum samples obtained from a naïve donor 1 day before vaccination on a sorbent with immobilized protein A showed that the IgG fraction did not contain Tf. However, Tf was detected in the IgG fractions obtained on the same column from serum samples of an individual on the 35th day after vaccination with Sputnik V and a COVID-19-recovered subject (Fig. 3a). Furthermore, IgGs obtained from sera of vaccinated and COVID-19-recovered individuals were able to bind peroxidase-labeled Lf, unlike IgGs purified from sera of naïve donors (Fig. 3b).


Overall, these data indicate that Spike-specific IgG antibodies can readily bind Tf and Lf, supporting our assumption of the role of the Spike, and specifically its RBD fragment, in the mimicry to host TfR ligands used in this study.



**Fig. 2** Distributions of levels of IgGs against RBD and Spike protein and Tf-binding with antibodies against RBD and Spike protein. Abscissa or ordinate designated by antigen immobilized on solid phase and a label used for detecting the level of antibodies. **a**—levels of IgGs against Spike protein and against RBD; **b**—levels of IgGs against Spike and Tf-binding with

antibodies against Spike; **c**—levels of IgGs against RBD and Tf-binding with antibodies against RBD; **d**—Tf-binding with antibodies against Spike and antibodies against RBD. Vaccinated ( $n=16$ ) marked as red circles, naïve ( $n=24$ ) as green triangles, COVID-19 convalescents ( $n=53$ ) as purple rhombs

**Fig. 3** Co-purification of Tf with IgGs from sera of vaccinated (red) and COVID-19 convalescent (purple) persons compared with serum of naïve donor (green) sampled 1 day before vaccination. **a**—concentration of Tf obtained after fractionation of 3 serum samples on a column with immobilized Protein A and determined by ELISA. From 1st to 9th fraction—elution of ballast proteins, from 15th fraction start elution of IgGs; **b**—binding of HRP-labeled Lf with solid phase immobilized IgGs isolated from serum samples or with purified Tf as negative control




### Analysis of spike protein binding with monoclonal antibodies against Lf

Since cross-reactivity between anti-Spike and anti-Lf antibodies could not be measured by the assays described above due to the direct binding of these antigens, two murine monoclonal antibodies against human Lf, namely from clones 3H5 and 3E11, were further tested. These antibodies differed by Lf-binding sites, e.g. 3E11 caused no dissociation of the complex formed by Lf with ceruloplasmin; in contrast, 3H5 antibody added to ceruloplasmin-Lf complex acted as a competitor (data not shown). Different concentrations

of Lf, as well as Spike protein biotinylated either on primary amino groups (Spike-A-Bi) or on carbohydrate moiety (Spike-C-Bi) were added to 3H5 or 3E11 Lf-specific antibodies immobilized on a solid phase (Fig. 4). 3E11 antibody bound cooperatively Lf and Spike-A-Bi: the higher Lf concentration was added, the more detectable was Spike protein. In contrast, 3H5 antibody made more evident the competition between Lf and Spike protein labeled with biotin hydrazide on the carbohydrate moiety. Thus, the two anti-Lf mAbs displayed cross-reactivity both with Lf and Spike protein, however, with noticeable differences. 3H5 performed as a target for competition of the two proteins,

**Fig. 4** Competitive ELISA of Lf and Spike protein on Lf-specific antibodies (3H5 or 3E11) immobilized on solid phase. Spike protein, labeled by biotin to primary amino groups (Spike-A-biotin, 200 ng/mL—blue triangles) or to carbohydrate moiety (Spike-C-biotin, 40 ng/mL—purple squares), and different concentrations of Lf were added in wells. Subsequent staining of biotin label by HRP-streptavidin was done



while 3E11 could bind the complex formed by Lf and Spike protein. Quite unexpectedly, the carbohydrate-mediated labeling was more sensitive to Spike protein binding with Lf, as compared with biotin labeling via primary amines.

Screening of TfR ligands for their ability to interfere with RBD interaction with SARS-CoV-2 neutralizing antibodies.

Screening among six mAbs against Spike protein for their capacity to bind RBD (Fig. 5a) and to suppress SARS-CoV-2 replication in a microneutralization assay demonstrated that S6 was the most effective in inhibiting viral replication in Vero cells, with an IC<sub>50</sub> value close to 0.1 μg/mL (Fig. 5b). The RBD-specific mAbs S2 and S4 could partially neutralize viral activity only at the highest concentrations 0.5–1 μg/mL, suggesting different affinity of mAbs S2, S4, and S6 and/or binding to different epitopes in RBD.


Interaction between S6-HRP and RBD immobilized on solid phase served as a target in the screening for interference among various ligands of TfR and sTfR itself. We assessed the binding of mAb S6-HRP to RBD in the presence of different concentrations of sTfR (0.7–44 nM), Tf or Lf (10–640 nM), aptamer against TfR1 (50–500 nM), as well as peptides RGD (2–120 μM) and GHAIYPRH (0.33–21 μM) (Fig. 5c). Importantly, sTfR showed the highest competitive

activity, with IC<sub>50</sub> value about 10 nM, while its physiological ligands i.e. Tf and Lf demonstrated virtually equal activity with IC<sub>50</sub> about 200 nM (Fig. 5c). Involvement of structural mimicry of RBD/Spike protein to Tf and Lf was also confirmed by competitive interference of other TfR ligands in the interaction between RBD and mAb S6. Aptamer against TfR1 and peptide GHAIYPRH, as well as peptide RGD, the synthetic integrin-binding motif, are involved in the binding of Lf and Tf with TfR1. Both Tf and Lf interacted with sTfR (Fig. 5d, lines 1–2 and 6–7). Interaction of RBD with Lf was stronger (Fig. 5d, line 8–9) than interaction of RBD with sTfR (Fig. 5d, line 4–5 and 10–11).

#### Analysis of Lf binding to spike protein and RBD

Interaction of Lf with Spike protein has been documented already in three studies (Campioni et al. 2021; Miotto et al. 2021; Cutone et al. 2022). Interaction of Lf with Spike protein prevents its interaction with anti-Lf mAbs (Fig. 4) and leads to many difficulties in assaying the cross-reactivity between antibodies raised against Spike protein or RBD and Lf. Interaction of Lf with RBD was detected by non-denaturing disc-PAGE (Fig. 6a–c). Binding of Lf with RBD was much more evident than Lf binding with Spike protein. Indeed, cationic Lf in complex with RBD migrated from stacking gel to






**Fig. 5** Screening for RBD-binding capacity of mAbs against Spike protein (panel a), SARS-CoV-2 neutralization assay (panel b), competitors' of RBD and mAbs S6 interaction (panel c), and interaction RBD with sTfR and Lf (panel d). **a** Spike-specific antibodies (S1-S6) screened for binding Spike and RBD immobilized on solid phase; detection by anti-mouse IgG-HRP. **b** SARS-CoV-2 neutralizing activity of S2, S4 and S6 mAbs. Serial dilutions of MABs in serum of SARS-CoV-2-naïve individual were mixed with SARS-CoV-2 virus, and Vero-CCL81 cells were infected with these mixtures. The inhibitory effect of the tested antibodies was measured by cell-ELISA and expressed as % of virus inhibition compared with the control virus-infected cells using four-parametrical non-linear regression analysis. **c** Anti-RBD-mAb (S6), labeled with HRP, and different concentrations of sTfR (0.7–44 nM), Tf or Lf (10–640 nM), aptamer against TfR1 (50–500 nM), peptides RGD (2–120  $\mu\text{M}$ ) and GHAIYPRH (0.33–21  $\mu\text{M}$ ) were added. **d** TAMRA-labeled proteins run in conditions of disc-electrophoresis without detergents: 1— $\text{Fe}_2\text{-Lf-TAMRA}$  (4 mg); 2— $\text{Fe}_2\text{-Lf-TAMRA}$  (4 mg)+sTfR (4 mg); 3—sTfR (4 mg); 4—RBD-TAMRA (2 mg)+sTfR (4 mg); 5—RBD-TAMRA (2 mg); 6— $\text{Fe}_2\text{Tf-TAMRA}$  (2 mg); 7— $\text{Fe}_2\text{Tf-TAMRA}$  (2 mg)+sTfR (4 mg); 8—RBD-TAMRA (4 mg)+ $\text{Fe}_2\text{Lf}$  (9 mg); 9—RBD-TAMRA (4 mg)+ $\text{Fe}_2\text{Lf}$  (9 mg)+sTfR (8 mg); 10—RBD-TAMRA (4 mg)+sTfR (8 mg); 11—RBD-TAMRA (4 mg)

resolving gel, while Spike protein in complex with Lf migrated from the middle of stacking gel to the space between stacking and resolving gel (Fig. 6a). Moreover, staining of Lf and RBD in Western blotting makes visible the migration of RBD from resolving to stacking gel (Fig. 6b), while using anti-Lf antibodies allowed to compare migration in electrophoresis of pure LF and its samples with RBD (Fig. 6c). Affinity of holo- and apo-Lf towards RBD was compared using RBD immobilized on

CM5-chip for SPR-assay (Fig. 6d, e). Affinity towards RBD was higher for holo-Lf as judged by rate constant  $4.3 \times 10^6 \text{ M}^{-1} \times \text{s}^{-1}$  and dissociation constant 16 nM in comparison with the respective values obtained for apo-Lf i.e.  $2.9 \times 10^6 \text{ M}^{-1} \times \text{s}^{-1}$  and 23 nM (Table 2).

Treatment of Vero E6 cells with apo-Lf and holo-Lf at concentrations 1–4 mg/mL significantly reduced SARS-CoV-2 titers, both for Wuhan and Delta lineages (Fig. 7). In all cases adding Lf at



**Fig. 6** Interaction of Lf with RBD and Spike protein in conditions of disc-electrophoresis without detergents (panel *a*, *b*, and *c*) and interaction of holo-Lf and apo-Lf (4–256 nM) with RBD immobilized on CM5-chip in SPR-assay (panels *d* and *e*). **a** Coomassie R-250 staining of gel after running samples: 1—RBD (4 μg); 2—RBD (4 μg)+LF (18 μg); 3—RBD (4 μg)+LF (9 μg); 4—RBD (4 μg)+LF (5 μg); 5—RBD (4 μg); 6—LF (18 μg); 7—Spike (2 μg); 8—Spike (2 μg)+LF (5 μg); 9—Spike (2 μg)+LF (9 μg); 10—Spike (2 μg)+LF (18 μg). **b** and **c** Western-blotting stained with 4-chloro-1-naphtol and hydrogen peroxide after incubation with HRP-labeled anti-RBD (0.5 μg/mL S2-HRP, panel *b*) and with anti-Lf (0.5 μg/mL 3E11-HRP, panel *c*) transferred to nitrocellulose from gel after running samples: 1—RBD (2 μg)+LF (4 μg); 2—RBD (2 μg)+LF (4 μg); 3—RBD (2 μg)+LF (8 μg); 4—RBD (2 μg)+LF (16 μg); 5—RBD (2 μg); 6—empty; 7—LF (16 μg); 8—LF (8 μg); 9—LF (4 μg); 10—LF (2 μg)

**Table 2** Kinetic parameters characterizing RBD interaction (immobilized on CM5-chip) with holo-Lf and apo-Lf, calculated from SPR data by Biacore X-100 software

Analyte	$k_{on}$ , $10^6 M^{-1} s^{-1}$	$k_{off}$ , $10^{-3} s^{-1}$	$K_d$ , nM	$R_{max}$ , RU
holo-Lf	$4.264 \pm 0.12$	$68 \pm 1$	$15.9 \pm 1.3$	$2810 \pm 12$
apo-Lf	$2.895 \pm 0.09$	$67 \pm 1$	$23.0 \pm 1.9$	$2251 \pm 11$

$k_{on}$  equilibrium association rate constant,  $k_{off}$  dissociation rate constant,  $K_d$  equilibrium dissociation constant,  $R_{max}$  analyte binding capacity


concentration 2 mg/mL substantially inhibited viral replication, and treatment with holo-Lf at this concentration resulted in the absence of detectable

(18 μg). **b** and **c** Western-blotting stained with 4-chloro-1-naphtol and hydrogen peroxide after incubation with HRP-labeled anti-RBD (0.5 μg/mL S2-HRP, panel *b*) and with anti-Lf (0.5 μg/mL 3E11-HRP, panel *c*) transferred to nitrocellulose from gel after running samples: 1—RBD (2 μg)+LF (4 μg); 2—RBD (2 μg)+LF (4 μg); 3—RBD (2 μg)+LF (8 μg); 4—RBD (2 μg)+LF (16 μg); 5—RBD (2 μg); 6—empty; 7—LF (16 μg); 8—LF (8 μg); 9—LF (4 μg); 10—LF (2 μg)

SARS-CoV-2 Wuhan variant (Fig. 7a). Although less pronounced reduction of Delta variant titers was seen in plates cultured in the presence of Lf, a statistically significant difference with the titer in the control wells was achieved for concentrations of 1, 2, and 4 mg/mL for both Lfs (Fig. 7b).

**Discussion**

In this paper we tried to verify a hypothesis about molecular mimicry of Spike protein, especially its RBD fragment, to natural ligands of TfR, Tf and Lf, and major findings of this paper were schematically summarized in Fig. 8. On the one side, if TfR is the critical receptor for SARS-CoV-2, its natural ligand, namely Lf, seems to be a promising competitor



**Fig. 7** Lf in apo- and holo-forms inhibits SARS-CoV-2 replication in Vero E6 cells. Cells were inoculated with 100 TCID<sub>50</sub> of B.1 Wuhan strain **a** or B.1.617.2 Delta strain **b** for 2 h, followed by the replacement of inoculum with culture medium containing either apo-Lf or holo-Lf at the indicated


concentrations. Two to three days post-infection, viral load in cell supernatants was determined by quantitative RT-PCR. Data were analyzed by two-way ANOVA with Tukey's post-hoc multiple analyses test. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$

of coronavirus cell entry; on the other side, cross-reactivity of antibodies against RBD of Spike protein with Tf and Lf can provoke severe symptoms of COVID-19 accompanied by an autoimmune response against Lf and Tf. Considering that replication cycle of SARS-CoV-2 mediated by TfR1 endocytosis can alter normal Tf-mediated influx of iron, it is not surprising that COVID-19-associated dysregulations of iron and oxygen metabolism, such as low levels of serum iron and erythropoietin accompanied by high levels of ferritin and hepcidin, can be corrected by Lf (Suriawinata and Mehta 2022). Anti-anemic and anti-hypoxic effects of Lf associated with down-regulation of IL-6 and hepcidin (Cutone et al. 2014; Rosa et al. 2017; Lepanto et al. 2019; Artym et al. 2021) and up-regulation of erythropoietin and ceruloplasmin (Pulina et al. 2010; Zakharova et al. 2012, 2018; Bonaccorsi di Patti et al. 2018; Kostevich et al. 2016; Sokolov et al. 2022b) seem to be a promising strategy for treating COVID-19 complications. It is worth noting that one of the first papers dedicated to the protective effect of Lf against SARS-CoV-2 infection also described the studies of antiviral effect of hypoxia, which decreased the content of heparan sulphate on cell surface by downregulating syndecan-1 expression via hypoxia-inducible factor-1 alpha (HIF-1 $\alpha$ )-dependent mechanism (Prieto-Fernández et al. 2021). It cannot be excluded that antiviral effect of Lf

is realized partly due to its HIF-1 $\alpha$ -stabilizing effect (Zakharova et al. 2012).

At the beginning of this study, we did not anticipate that human antibodies against RBD and Spike protein itself would circulate in complex with Tf. However, this phenomenon explains why early attempts to detect cross-reactivity of anti-RBD or anti-Spike antibodies using either Tf on solid phase or labeled Tf were puzzling. Indeed, either reverse dependence was found between anti-RBD and anti-Spike levels and their capacity to bind Tf immobilized on solid phase (Fig. S3a, b) or, in case of labeled Tf, no dependence was observed (Fig. S3c, d).

However, when labeled anti-Tf antibody were used, we found a strong correlation between the levels of anti-RBD and anti-Spike IgG and the level of Tf bound to these antibodies (Fig. S3e–h, and Fig. 2). Importantly, in the preliminary control experiments, anti-Tf was tested for the absence of cross-reactivity with RBD and Spike protein. Indeed, the level of Tf binding in the assay of serum samples obtained from naïve donors was negligible. Considering the difficulties of detecting separately IgM and IgA, we had no aim to study the cross-reactivity with Tf of anti-RBD and anti-Spike protein belonging to each of those Ig classes, though their input in the cross-reactivity cannot be excluded. Thus, the setup of the 3rd assay accounts for possible detection of human IgA and



**Fig. 8** An overview of the study findings that verify our hypothesis about molecular mimicry of Spike protein of SARS-CoV-2 with TfR ligands

IgM raised against RBD and Spike protein, that are cross-reactive to Tf (Fig. S2). Given that Tf binding can occur not only due to IgG, but IgA and IgM as well, the array of most points in the distribution of Tf binding above the approximating lines characterizing the anti-Spike IgG levels (Fig. 2b) and anti-RBD IgG distribution (Fig. 2c), can result from the involvement of other classes of Igs against Spike and RBD in Tf binding. TfR mediates penetration of Tf through the blood–brain barrier (Liang et al. 2018; Pardridge 2022). Since the immune response to SARS-CoV-2 induces binding of plasma Tf to anti-RBD and anti-Spike antibodies, this effect may alter iron traffic from the bloodstream into the brain. On the other hand, this

may contribute to the TfR-mediated penetration of the virus through the blood–brain barrier.

Interestingly, not only human antibodies raised against RBD and Spike protein in response to SARS-CoV-2 infection or to vaccination with Sputnik V cross-reacted with human Tf and Lf (Figs. 2 and 3), but also Lf-specific mAbs 3H5 and 3E11 cross-reacted with Spike protein, as well as mAb S6 against RBD of Spike protein cross-reacted with TfR ligands (Figs. 4 and 5c). Since we observed cross-reactivity of Spike protein with mAbs 3H5 and 3E11 that were raised after immunization of mice with human Lf, we carefully checked the Spike protein for the absence of contamination with Lf. Importantly that all steps from immunizing mice to cloning hybridomas that



produced anti-Lf mAbs for this study, were completed by October 2019, before the COVID-19 pandemic and the first receipt of the SARS-CoV-2 Spike protein by our laboratory.

To provide further evidence of anti-RBD and anti-Spike antibody binding with Tf and Lf, we used serum samples from naïve, vaccinated, and COVID-19-recovered donors and purified IgG on Protein A affinity sorbent. Importantly, the serum samples of naïve and vaccinated donor were obtained from the same subjects 1 day before and on the 35th day after vaccination. Tf was present only in IgG fractions purified from the sera of vaccinated and convalescent donors, and those IgGs also bound HRP-labeled Lf. IgGs obtained from the sera of naïve donors had no traces of Tf and did not bind the labeled Lf. Autoantibodies against Tf have been documented in several case-report studies of acquired anemia and myeloma-associated hypersideremia (Westerhausen and Meuret 1977; Numata et al. 1991; Alyanakian et al. 2007; Forni et al. 2008). The “gold standard” of such studies is co-purification of Tf with antibodies isolated by affinity chromatography from the patient sera (Forni et al. 2013). High concentrations of anti-Tf in autoimmune pathologies lead to dysregulation of iron metabolism, including increased levels of serum iron, Tf, ferritin, iron saturation of Tf and total serum iron-binding capacity (Alyanakian et al. 2007; Forni et al. 2008). Few of these symptoms coincide with dysregulations of iron metabolism observed in the COVID-19 patients (Suriawinata and Mehta 2022), which can be explained by much lower level of Tf-cross-reactive antibodies induced by SARS-CoV-2 infection, as compared with anti-Tf serum level in those case-report studies. However, an increase of Tf expression induced by SARS-CoV-2 infection was described (McLaughlin et al. 2020), which probably increased the risk of hypercoagulation (Tang et al. 2020b). Increased serum iron, ferritin and Tf saturation in intensive care unit patients during the 3rd–6th day of COVID-19 were documented (Bolondi et al. 2020). In a pioneering study by Westerhausen and Meuret, immunosuppressive therapy in the so-called transferrin-immune complex disease only partially restored iron metabolism (Westerhausen and Meuret 1977). Extensive studies of the last decade confirmed the notion of anti-Tf reactivity of antibodies in patients with multiple sclerosis (Colomba et al. 2014).

Autoantibodies against Lf have been documented in such pathologies as anti-neutrophil cytoplasm antibodies-associated systemic vasculitis, chronic obstructive pulmonary disease, systemic *lupus erythematosus*, rheumatoid arthritis, ulcerative colitis, Crohn’s disease, autoimmune hepatitis (also associated with HIV-1 infections) (Peen et al. 1993; Dapsanse et al. 2001; Tan et al. 2014; Ma et al. 2020). Interestingly, antibodies cross-reacting with Lf and myeloperoxidase were reported in renal pathology associated with formation of anti-neutrophil cytoplasm autoantibodies (Esnault et al. 1994). Lf-containing immunocomplexes featured extraordinary potent proinflammatory properties against human monocytes and macrophages (Hu et al. 2017). Emergence of anti-Lf causes an increase in nitrite levels (Dapsanse et al. 2001), alteration of iron-saturation of Lf (Audrain et al. 1996), enhancement of neutrophil extracellular traps formation (NETs) (Shida et al. 2016). The latter is a well-known feature of severe COVID-19 (Ackermann et al. 2021). Effect of Lf against NETs formation is described in several studies (Okubo et al. 2016; Grigorieva et al. 2022) and this property makes it a promising remedy in mitigating the severity of COVID-19.

In ELISA with anti-Lf mAb 3E11 immobilized on solid phase, Lf and Spike protein were bound cooperatively, but the intensity of Spike binding depended on the mode of its biotinylation. When biotin was attached to primary amino groups, the interaction of Spike with mAb 3E11 was more intense than in case of biotinylated carbohydrates (Fig. 4). Meanwhile, anti-Lf mAb 3H5 immobilized on solid phase mostly bound Lf. The latter behaved as competitor of Spike protein, especially carbohydrate-biotinylated, for interaction with 3H5. It can be concluded that carbohydrate moieties of Spike protein are more important for binding with Lf than amino acids with primary amino groups. Given that the interaction of Lf with ceruloplasmin is not dissociated by 3E11, unlike 3H5, which behaves as a competitor for ceruloplasmin binding to Lf, we can assume that the interaction site of the Spike protein overlaps with ceruloplasmin-binding site of Lf. The latter was mapped in our previous studies that provided evidence of competition for binding with Lf between ceruloplasmin and DNA, lipopolysaccharide, and heparin. All these ligands bind with N-terminal polycationic site of Lf. Peptides RRRR and



RKVR, corresponding to <sup>2</sup>RRRR<sup>5</sup> and <sup>25</sup>RKVR<sup>28</sup> of Lf act in the same way (Pulina et al. 2002; Sokolov et al. 2006). Involvement of N-terminal polycationic site in Lf into the interaction with ceruloplasmin was confirmed by structural studies of their complexes (Sabatucci et al. 2007; Samygina et al. 2013). Therefore, it is likely that the Spike-binding site includes the N-terminal polycationic site of Lf.

Three independent approaches were used in this study to explore the interaction of Lf with RBD of Spike protein:

- 1) Competitive ELISA showed that Lf acts as a competitor of interaction between RBD immobilized on solid phase and HRP-labeled mAb against Spike protein (S6-HRP) which neutralizes SARS-CoV-2 infection in Vero cells (Fig. 5c);
- 2) Lf shifted RBD band in disc-electrophoresis without detergents, and the same effect was obtained by Western blotting (Fig. 5a–c), which suggests direct binding of the two proteins;
- 3) In SPR-assay, the interaction of RBD immobilized on CM5-chip with apo-Lf and holo-Lf was characterized by  $K_d \sim 23$  and 16 nM, respectively (Fig. 6d, e; Table 2). Importantly, the interaction of Lf with RBD was characterized by higher affinity as compared with mAb S6 against Spike protein and anti-Lf mAb 3E11-HRP which was used for Lf detection by Western blotting (Fig. 6c). Therefore, when antibodies against Lf and RBD are produced during the immune response, the latter are of interest because they neutralized coronavirus infection, yet their interaction with antigens was weaker than their mutual interference. That is why Lf seems a prospective competitor of SARS-CoV-2 in its interaction with TfR. Such property of Lf should not be neglected, but the fact that Lf interacts with TfR has been omitted from a number of the most recent reviews concerning its functions (Mahidhara et al. 2015; Kell et al. 2020; Bartolomé et al. 2022).

Interaction of Lf with RGD-motif was well documented for TfR1 (Kawabata et al. 1999) and extracellular matrix proteins i.e., fibronectin and vitronectin (Sakamoto et al. 2006). Interestingly, <sup>403</sup>RGD<sup>405</sup>-motif in RBD of Spike protein is missing in previous human coronavirus variants, but remains

conserved in SARS-CoV-2 strains (Liu et al. 2020; Othman et al. 2022; Nassar et al. 2021). Considering the competitive effect of sTfR and synthetic RGD on the interaction of RBD with SARS-CoV-2-neutralizing mAb S6 (Fig. 5c), the importance of RGD-motif in RBD for interacting with its cellular receptor, namely TfR1, can be proposed. In view of extensive studies of TfR1 as a target for antibody-mediated cancer therapy (Candelaria et al. 2021), similar studies of anti-TfR1 potential in suppressing anti-SARS-CoV-2 activity are warranted.

Inhibition of SARS-CoV-2 infection was practically the same for apo-Lf and holo-Lf tested on B.1 Wuhan strain and B.1.617.2 Delta strain (Fig. 7). Holo-Lf in comparison with apo-Lf was more efficient only when taken in concentration 2 mg/mL in case of B.1 Wuhan strain infection (Fig. 7a). Similar efficiency of apo- and holo-Lf against infection can be interpreted at least in three ways: (1) close affinity of RBD both to apo- and holo-Lf presumes their similar efficiency; (2) both apo-Lf and holo-Lf can interact with TfR1; (3) high affinity of apo-Lf to ferric ions can result in formation of holo-Lf. Taking into account down-regulation of TfR1 by holo-Lf (Zhang et al. 2021) this form will be our choice in future studies. In contrast, apo-form LF can increase *TfR1* expression via HIF-dependent pathway, which can result in undesired multiplying of the sites for viral uptake.

The details of studies demonstrating protective effects of Lf against SARS-CoV-2 in infected cells are summarized in Table 3. Taking into account that heparin is one of the ligands with the highest affinity for the polycationic site in Lf, it is not surprising that in all studies of the antiviral activity of Lf, the addition of heparin abolished its ability to inhibit SARS-CoV-2 (Prieto-Fernández et al. 2021; Mirabelli et al. 2021; Lai et al. 2022).

In their study, Mirabelli et al. performed an analysis of transcriptomic changes triggered by Lf in non-infected iAEC2 cells. Addition of 6.25 mM Lf to these cells resulted in significant up- and down-regulation of 1016 and 1023 genes, respectively. Up-regulated genes are involved in epithelial-mesenchymal transition, TNF- $\alpha$  signalling via NF- $\kappa$ B, and hypoxia (Mirabelli et al. 2021). This is an independent indication of Lf involvement in the regulation of inflammation and tolerance to hypoxia.

**Table 3** In vitro anti-SARS-CoV-2 effects of Lf

Study	Type of virus or pseudovirus	Lf used in study	Lf, $\mu\text{M}$ (mg/mL)	Cell culture	Dose of virus and mode of Lf adding	Outcomes of Lf addition
Campione et al. 2021	SARS-CoV-2 (isolated from nasopharyngeal specimen of a positive COVID-19 patient)	Bovine Lf (7% saturation by iron, Armor Proteines Industries)	1.3 (0.1) 1.3 and 6.4 (0.1 and 0.5)	Vero E6 Caco-2	and 0.01 MOI, 1 h preincubation with SARS-CoV-2 and 0.01 MOI, 6, 24 and 48 h preincubation with SARS-CoV-2 or with cells	Decrease $\sim 1$ log at MOI 0.1 and $\sim 2$ log at MOI 0.01 0.5 mg/mL of Lf preincubated with Caco-2 cells or viral particles showed a higher decrease in the viral load at MOI 0.1 and 0.01
Prieto-Fernández et al. 2021	Pseudotyped viral particles expressing the spike protein of SARS-CoV-2	Human Lf (90% saturation by iron, recombinant, expressed in rice, L1294—Sigma-Aldrich)	1000, 5000 and 10,000 (78, 390, 780)	Vero E6 and NCI-H460	MOI, 48 h incubation	Blocks the binding of RBD to the surface of epithelial cells with IC50 close to 1 $\mu\text{M}$ for Vero E6 and lower than 1 $\mu\text{M}$ for NCI-H460
Salaris et al. 2021	SARS-CoV-2 (isolated from a patient)	Bovine Lf (Globoferina—SOFAR SpA)	1.3 (0.1)	Caco-2	2:1 MOI, 3 h preincubation before SARS-CoV-2 infection with and without wash	Viral titer of the harvested supernatants revealed that Lf pre-infection treatments (washed and unwashed) resulted in 24% and 7% inhibition of infection
Mirabelli et al. 2021	SARS-CoV-2 (isolate USA-WA1/2020, NR-52281)	Bovine Lf (from bovine colostrum, L4765—Sigma-Aldrich) Human Lf (LFT-8196H—Creative BioMart)	0.01–5000 (0.0008–390)	iAEC2 (derived alveolar epithelial type 2 cells)	10 MOI, 48 h post infection	IC <sub>50</sub> $\sim 45$ nM IC <sub>50</sub> $\sim 466$ nM
		Human apo- and holo-Lf	0.00625–6.25 (0.0005–0.49)	Huh7	0.2–10 MOI, 48 h post infection	Decrease $\sim 7$ log at MOI 0.2 by 6.25 $\mu\text{M}$ Lf

**Table 3** (continued)

Study	Type of virus or pseudovirus	Lf used in study	Lf, $\mu\text{M}$ (mg/mL)	Cell culture	Dose of virus and mode of Lf adding	Outcomes of Lf addition
Hu et al. 2021	SARS-CoV-2 pseudovirus	Human Lf (from human milk, L4894—Sigma-Aldrich)  Bovine Lf (from bovine milk, L9507—Sigma-Aldrich)	0.051–12.8 (0.004–1)	Vero E6, Calu-3, HEK293(-ACE2)	0.1 MOI, 48 h post infection	Vero E6— IC <sub>50</sub> ~0.16 mg/mL; Calu-3—IC <sub>50</sub> ~0.1 mg/mL, HEK293T— IC <sub>50</sub> ~0.03 mg/mL  Vero E6— IC <sub>50</sub> ~0.05 mg/mL; Calu-3— IC <sub>50</sub> ~0.05 mg/mL; HEK293T— IC <sub>50</sub> ~0.03 mg/mL Antiviral activity of bovine Lf is diminished dose-dependently by exogenously added heparin
Lai et al. 2022	SARS-CoV-2 pseudovirus	Human Lf (iron-saturated, 61,327—Sigma-Aldrich), Bovine Lf (S24749—Yuanye Bio), Goat Lf (recombinant, abx067679—Abbexa)	0.26–25.6 (0.02–2)	Vero E6	650 TCID50/well, 24 h pretreatment of cells with Lf	Close to 100% inhibition of infection by 2 mg/mL of any Lf used Inhibitory effect of Lf decreased with the addition of heparin in a concentration-dependent manner
Worting et al. 2022	SARS-CoV-2 (WAI strain)	Bovine Lf (from bovine milk, Bioferrin 2000—Glanbia Nutritional)	0.005–5.1 (0.0004–0.4)	H1437 (human lung adenocarcinoma)	5 MOI, 24 h pretreatment of cells with Lf and 48 h post infection	IC <sub>50</sub> ~0.02 mg/mL
Cutone et al., 2022	Pseudovirus	Human Lf (Sigma-saturation), Bovine Lf (Saputo Dairy, Australia, 11% iron saturation)	1.3 and 6.4 (0.1 and 0.5)	Vero E6, Caco-2, THP-1	10 MOI; 1 h preincubated of pseudovirus or cells with Lf then infected 8 h	Inhibition of Pseudovirus entry was invariably lower with human Lf than bovine Lf, effects of Lfs were not restricted to a specific cell line

Table 3 (continued)

Study	Type of virus or pseudovirus	Lf used in study	Lf, $\mu\text{M}$ (mg/mL)	Cell culture	Dose of virus and mode of Lf adding	Outcomes of Lf addition
Present study	SARS-CoV-2 (B.1 Wuhan strain and B.1.617.2 Delta strain)	Human Lf (recombinant apo-form—10% saturation by iron; holo-Lf—100% saturation by iron, “CAPRABEL™”)	6.4–51.2 (0.5–4)	Vero E6	100 TCID <sub>50</sub> , 2 h infection and incubation with Lf 48 h (for B.1 Wuhan strain) or 72 h (for B.1.617.2 Delta strain)	Decrease ~2–4 log by 2 and 4 mg/mL apo- and holo-Lf

Summarizing the literature data and the results obtained in this study, we can conclude that antiviral effect of Lf can be mediated by several pleiotropic effects of this moonlighting protein: (1) Lf can directly interact with RBD of Spike protein with high affinity characterized by  $K_d$  from 16 nM for holo-Lf to 23 nM for apo-Lf; (2) Competition between Lf and RBD of Spike protein for binding with TfR1 can prevent TfR1-mediated endocytosis of SARS-CoV-2; (3) anti-inflammatory activity of Lf includes down-regulation of IL-6 and neutrophil extracellular trap formation; (4) Lf exhibits anti-hypoxic and anti-anaemic effects. All these effects of Lf seem like promising approaches to reducing the severity of COVID-19 and post-COVID syndrome.

**Acknowledgements** We thank Dr. Alexandra Rak for her help in maintaining continuous cell lines. We also thank all participants who donated blood and placenta tissue for this study.

**Author contributions** Conceptualization: AVS, INIS; Methodology: AVS, INIS, DAM, VAK, NPG, NAG, NNN; Formal analysis and investigation: AVS, INIS, DAM, VAK, NPG, AYE, VAM, YMB; Validation: YMB, YAZ; Writing—original draft preparation: AVS, INIS; Writing—review and editing: INIS, VBV; Funding acquisition: INIS; Resources: ASK, IVS, AIB; Supervision: INIS, LGR, VBV.

**Funding** This work was supported by State assignment of the Federal State Budgetary Institution “Research Institute of Experimental Medicine” 0557-2019-0009 and FGWG-2022-0001. Equipment of the Shared Core Facilities “Human microbiome” at the Institute of Experimental Medicine was exploited upon synthesis of peptides for this research.

#### Declarations

**Competing interests** The authors declare no competing interests.

**Conflict of interest** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

#### References

- Ackermann M, Anders H-J, Bilyy R et al (2021) Patients with COVID-19: in the dark-NETs of neutrophils. *Cell Death Differ* 28:3125–3139. <https://doi.org/10.1038/s41418-021-00805-z>
- Aleem A, Akbar Samad AB, Slenker AK (2022) Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 10, 2022.

- Alkhateeb AA, Buckett PD, Gardeck AM et al (2015) The small molecule ferristatin II induces hepatic hepcidin expression in vivo and in vitro. *Am J Physiol Gastrointest Liver Physiol* 308:G1019–G1026. <https://doi.org/10.1152/ajpgi.00324.2014>
- Alyanakian MA, Taes Y, Bensaïd M et al (2007) Monoclonal immunoglobulin with antitransferrin activity: a rare cause of hypersideremia with increased transferrin saturation. *Blood* 109:359–361. <https://doi.org/10.1182/blood-2006-05-023762>
- Amanat F, White KM, Miorin L et al (2020) An in vitro micro-neutralization assay for SARS-CoV-2 serology and drug screening. *Curr Protoc Microbiol* 58:e108. <https://doi.org/10.1002/cpmc.108>
- Anderson NL, Nance SL, Pearson TW et al (1982) Specific antiserum staining of two-dimensional electrophoretic patterns of human plasma proteins immobilized on nitricellulose. *Electrophoresis* 3:135–142
- Artym J, Zimecki M, Kruzel ML (2021) Lactoferrin for prevention and treatment of anemia and inflammation in pregnant women: a comprehensive review. *Biomedicines* 9:898. <https://doi.org/10.3390/biomedicines9080898>
- Audrain MA, Gourbil A, Muller JY, Esnault LM (1996) Anti-lactoferrin autoantibodies: relation between epitopes and iron-binding domain. *J Autoimmun* 9:569–574. <https://doi.org/10.1006/jaut.1996.0076>
- Ayo A, Laakkonen P (2021) Peptide-based strategies for targeted tumor treatment and imaging. *Pharmaceutics* 13:481. <https://doi.org/10.3390/pharmaceutics13040481>
- Baker HM, Baker EN (2004) Lactoferrin and iron: structural and dynamic aspects of binding and release. *Biometals* 17:209–216. <https://doi.org/10.1023/b:biom.0000027694.40260.70>
- Bartolomé F, Rosa L, Valenti P et al (2022) Lactoferrin as immune-enhancement strategy for SARS-CoV-2 infection in Alzheimer's disease patients. *Front Immunol* 13:878201. <https://doi.org/10.3389/fimmu.2022.878201>
- Bolondi G, Russo E, Gamberini E et al (2020) Iron metabolism and lymphocyte characterisation during Covid-19 infection in ICU patients: an observational cohort study. *World J Emerg Surg* 15:41. <https://doi.org/10.1186/s13017-020-00323-2>
- Bonaccorsi di Patti MC, Cutone A, Polticelli F et al (2018) The ferroportin-ceruloplasmin system and the mammalian iron homeostasis machine: regulatory pathways and the role of lactoferrin. *Biometals* 31:399–414. <https://doi.org/10.1007/s10534-018-0087-5>
- Britigan BE, Serody JS, Cohen MS (1994) The role of lactoferrin as an anti-inflammatory molecule. *Adv Exp Med Biol* 357:143–156. [https://doi.org/10.1007/978-1-4615-2548-6\\_14](https://doi.org/10.1007/978-1-4615-2548-6_14)
- Brock JH (1980) Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the newborn infant. *Arch Dis Child* 55:417–421. <https://doi.org/10.1136/adc.55.6.417>
- Brown JX, Buckett PD, Wessling-Resnick M (2004) Identification of small molecule inhibitors that distinguish between non-transferrin bound iron uptake and transferrin-mediated iron transport. *Chem Biol* 11:407–416. <https://doi.org/10.1016/j.chembiol.2004.02.016>
- Byrne SL, Buckett PD, Kim J et al (2013) Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo. *PLoS ONE* 8:e70199. <https://doi.org/10.1371/journal.pone.0070199>
- Campione E, Lanna C, Cosio T et al (2021) Lactoferrin against SARS-CoV-2: in vitro and in silico evidences. *Front Pharmacol* 12:666600. <https://doi.org/10.3389/fphar.2021.666600>
- Candelaria PV, Leoh LS, Penichet ML, Daniels-Wells TR (2021) Antibodies targeting the transferrin receptor 1 (TfR1) as direct anti-cancer agents. *Front Immunol* 12:607692. <https://doi.org/10.3389/fimmu.2021.607692>
- Cantuti-Castelvetri L, Ojha R, Pedro LD et al (2020) Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science* 370:856–860. <https://doi.org/10.1126/science.abd2985>
- Cavezzi A, Menicagli R, Troiani E, Corrao S (2022) COVID-19, cation dysmetabolism, sialic acid, CD147, ACE2, viroporins, hepcidin and ferroptosis: a possible unifying hypothesis. *Research* 11:102. <https://doi.org/10.12688/f1000research.108667.2>
- Colomba P, Fontana S, Salemi G et al (2014) Identification of biomarkers in cerebrospinal fluid and serum of multiple sclerosis patients by immunoproteomics approach. *Int J Mol Sci* 15:23269–23282. <https://doi.org/10.3390/ijms151223269>
- Cutone A, Frioni A, Berluti F et al (2014) Lactoferrin prevents LPS-induced decrease of the iron exporter ferroportin in human monocytes/macrophages. *Biometals* 27:807–813. <https://doi.org/10.1007/s10534-014-9742-7>
- Cutone A, Rosa L, Bonaccorsi di Patti MC et al (2022) Lactoferrin binding to Sars-CoV-2 Spike glycoprotein protects host from infection, inflammation and iron dysregulation. *Res Sq*. <https://doi.org/10.21203/rs.3.rs-1605740/v1>
- Dakal TC (2021) SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19. *Immunobiology* 226:152021. <https://doi.org/10.1016/j.imbio.2020.152021>
- Daly JL, Simonetti B, Klein K et al (2020) Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science* 370:861–865. <https://doi.org/10.1126/science.abd3072>
- Dapsanse V, Defér MC, Follézou JY et al (2001) Differential pattern in circulating nitrogen derivatives, lactoferrin, and anti-lactoferrin antibodies in HIV type 1 and HIV type 2 infections. *AIDS Res Hum Retrovir* 17:1041–1045. <https://doi.org/10.1089/088922201300343726>
- Davis BJ (1964) Disc electrophoresis. II. Method and application to human serum proteins. *Ann N Y Acad Sci* 121:404–427
- Dewan A, Jani JP, Patel JS et al (1988) Benzidine and its acetylated metabolites in the urine of workers exposed to direct black 38. *Arch Environ Health* 43:269–272. <https://doi.org/10.1080/00039896.1988.10545948>
- Dubljevic V, Sali A, Goding JW (1999) A conserved RGD (Arg-Gly-Asp) motif in the transferrin receptor is required for binding to transferrin. *Biochem J* 341:11–14
- Elzoghby AO, Abdelmoneem MA, Hassanin IA et al (2020) Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier & targeting ligand. *Biomaterials* 263:120355. <https://doi.org/10.1016/j.biomaterials.2020.120355>



- Esnault VL, Short AK, Audrain MA et al (1994) Autoantibodies to lactoferrin and histone in systemic vasculitis identified by anti-myeloperoxidase solid phase assays. *Kidney Int* 46(1):153–160. <https://doi.org/10.1038/ki.1994.254>
- Fling SP, Gregerson DS (1986) Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. *Anal Biochem* 155:83–88
- Forni GL, Girelli D, Lamagna M et al (2008) Acquired iron overload associated with antitransferrin monoclonal immunoglobulin: a case report. *Am J Hematol* 83:932–934. <https://doi.org/10.1002/ajh.21297>
- Forni GL, Pinto V, Musso M et al (2013) Transferrin-immune complex disease: a potentially overlooked gammopathy mediated by IgM and IgG. *Am J Hematol* 88:1045–1049. <https://doi.org/10.1002/ajh.23558>
- Godínez-Chaparro B, Guzmán-Mejía F, Drago-Serrano ME (2021) Lactoferrin and its potential impact for the relief of pain: a preclinical approach. *Pharmaceuticals* 14:868. <https://doi.org/10.3390/ph14090868>
- Grigorieva DV, Gorudko IV, Grudinina NA et al (2022) Lactoferrin modified by hypohalous acids: partial loss in activation of human neutrophils. *Int J Biol Macromol* 195:30–40. <https://doi.org/10.1016/j.ijbiomac.2021.11.165>
- Hu L, Hu X, Long K et al (2017) Extraordinarily potent pro-inflammatory properties of lactoferrin-containing immunocomplexes against human monocytes and macrophages. *Sci Rep* 7:4230. <https://doi.org/10.1038/s41598-017-04275-7>
- Hu Y, Meng X, Zhang F et al (2021) The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. *Emerg Microbes Infect* 10:317–330. <https://doi.org/10.1080/22221751.2021.1888660>
- Jackson CB, Farzan M, Chen B, Choe H (2022) Mechanisms of SARS-CoV-2 entry into cells. *Nat Rev Mol Cell Biol* 23:3–20. <https://doi.org/10.1038/s41580-021-00418-x>
- Jennifer B, Berg V, Modak M et al (2020) Transferrin receptor 1 is a cellular receptor for human heme-albumin. *Commun Biol* 3:621. <https://doi.org/10.1038/s42003-020-01294-5>
- Kanevsky VYu, Pozdnyakova LP, Katukov VYu, Severin SE (1997) Isolation of the transferrin receptor from human placenta. *Biochem Mol Biol Int* 42:309–314. <https://doi.org/10.1080/15216549700202701>
- Kawabata H, Yang R, Hiramata T et al (1999) Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. *J Biol Chem* 274:20826–20832. <https://doi.org/10.1074/jbc.274.30.20826>
- Kawakami H, Dosako S, Lönnnerdal B (1990) Iron uptake from transferrin and lactoferrin by rat intestinal brush-border membrane vesicles. *Am J Physiol* 258:G535–G541. <https://doi.org/10.1152/ajpgi.1990.258.4.G535>
- Kell DB, Heyden EL, Pretorius E (2020) The biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria. *Front Immunol* 11:1221. <https://doi.org/10.3389/fimmu.2020.01221>
- Kostevich VA, Sokolov AV, Kozlov SO et al (2016) Functional link between ferroxidase activity of ceruloplasmin and protective effect of apo-lactoferrin: studying rats kept on a silver chloride diet. *Biometals* 29:691–704. <https://doi.org/10.1007/s10534-016-9944-2>
- Kronstein-Wiedemann R, Stadtmüller M, Traikov S et al (2022) SARS-CoV-2 infects red blood cell progenitors and dysregulates hemoglobin and iron metabolism. *Stem Cell Rev Rep* 18:1809–1821. <https://doi.org/10.1007/s12015-021-10322-8>
- Kumar S, Sheokand N, Mhadeshwar MA et al (2012) Characterization of glyceraldehyde-3-phosphate dehydrogenase as a novel transferrin receptor. *Int J Biochem Cell Biol* 44:189–199. <https://doi.org/10.1016/j.biocel.2011.10.016>
- Lai X, Yu Y, Xian W et al (2022) Identified human breast milk compositions effectively inhibit SARS-CoV-2 and variants infection and replication. *iScience* 25:104136. <https://doi.org/10.1016/j.isci.2022.104136>
- Lebrón JA, West AP Jr, Bjorkman PJ (1999) The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. *J Mol Biol* 294:239–245. <https://doi.org/10.1006/jmbi.1999.3252>
- Lepanto MS, Rosa L, Paesano R et al (2019) Lactoferrin in aseptic and septic inflammation. *Molecules* 24:1323. <https://doi.org/10.3390/molecules24071323>
- Li YQ, Guo C (2021) A review on lactoferrin and central nervous system diseases. *Cells* 10:1810. <https://doi.org/10.3390/cells10071810>
- Liang M, Gao C, Wang Y et al (2018) Enhanced blood-brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles. *Drug Deliv* 25:1652–1663. <https://doi.org/10.1080/10717544.2018.1494223>
- Liu Z, Xiao X, Wei X et al (2020) Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *J Med Virol*. <https://doi.org/10.1002/jmv.25726>
- Luck AN, Mason AB (2013) Structure and dynamics of drug carriers and their interaction with cellular receptors: focus on serum transferrin. *Adv Drug Deliv Rev* 65(8):1012–1019. <https://doi.org/10.1016/j.addr.2012.11.001>
- Ma A, Wen L, Yin J et al (2020) Serum levels of autoantibodies against extracellular antigens and neutrophil granule proteins increase in patients with COPD compared to non-COPD smokers. *Int J Chron Obstruct Pulmon Dis* 15:189–200. <https://doi.org/10.2147/COPD.S235903>
- Mahidhara G, Kanwar RK, Roy K, Kanwar JR (2015) Oral administration of iron-saturated bovine lactoferrin-loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism. *Int J Nanomed* 10:4081–4098. <https://doi.org/10.2147/IJN.S75877>
- Makowski L, Olson-Sidford W (2021) Biological and clinical consequences of integrin binding via a rogue RGD motif in the SARS-CoV-2 spike protein. *Viruses* 13:146. <https://doi.org/10.3390/v13020146>
- Malhotra H, Kumar M, Chauhan AS et al (2019) Moonlighting protein glyceraldehyde-3-phosphate dehydrogenase: a cellular rapid-response molecule for maintenance of iron homeostasis in hypoxia. *Cell Physiol Biochem* 52:517–531. <https://doi.org/10.33594/000000037>
- Masson PL, Heremans JF, Dive CH (1966) Studies on lactoferrin, an iron-binding protein common to many external

- secretions. *Clin Chim Acta* 14:735–739. [https://doi.org/10.1016/0009-8981\(66\)90004-0](https://doi.org/10.1016/0009-8981(66)90004-0)
- Masson PL (1970) In: Arscia SA (ed.) *La lactoferrine. proteine des secretions externes et des leucocytes neutrophiles*, Brussels
- Matyushenko V, Isakova-Sivak I, Kudryavtsev I et al (2021) Detection of IFN $\gamma$ -secreting CD4+ and CD8+ memory T cells in COVID-19 convalescents after stimulation of peripheral blood mononuclear cells with live SARS-CoV-2. *Viruses* 13:1490. <https://doi.org/10.3390/v13081490>
- McLaughlin KM, Bechtel M, Bojkova D et al (2020) COVID-19-related coagulopathy-is transferrin a missing link? *Diagnostics* 10:539. <https://doi.org/10.3390/diagnostics10080539>
- Miotto M, Di Rienzo L, Bò L et al (2021) Molecular mechanisms behind anti SARS-CoV-2 action of lactoferrin. *Front Mol Biosci* 8:607443. <https://doi.org/10.3389/fmolb.2021.607443>
- Mirabelli C, Wotring JW, Zhang CJ et al (2021) Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. *Proc Natl Acad Sci USA* 118:e2105815118. <https://doi.org/10.1073/pnas.2105815118>
- Naidu SAG, Clemens RA, Naidu AS (2022) SARS-CoV-2 infection dysregulates host iron (Fe)-redox homeostasis (Fe-R-H): role of Fe-redox regulators, ferroptosis inhibitors, anticoagulants, and iron-chelators in COVID-19 control. *J Diet Suppl.* <https://doi.org/10.1080/19390211.2022.2075072>
- Nassar A, Ibrahim IM, Amin FG et al (2021) A review of human coronaviruses' receptors: the host-cell targets for the crown bearing viruses. *Molecules* 26:6455. <https://doi.org/10.3390/molecules26216455>
- Norris EG, Pan XS, Hocking DC (2022) Receptor binding domain of SARS-CoV-2 is a functional  $\alpha$ v-integrin agonist. *bioRxiv*. <https://doi.org/10.1101/2022.04.11.487882>
- Numata Y, Tanioka F, Yoshida K et al (1991) Ascertainment of IgA1 (kappa)-transferrin complex in a case of multiple myeloma associated with hypersiderinemia. *Jpn J Med* 30:498–503. <https://doi.org/10.2169/internalmedicine1962.30.498>
- Okubo K, Kamiya M, Urano Y et al (2016) Lactoferrin suppresses neutrophil extracellular traps release in inflammation. *EBioMedicine* 10:204–215. <https://doi.org/10.1016/j.ebiom.2016.07.012>
- Othman H, Messaoud HB, Khamessi O et al (2022) SARS-CoV-2 spike protein unlikely to bind to integrins via the Arg-Gly-Asp (RGD) motif of the receptor binding domain: evidence from structural analysis and micro-scale accelerated molecular dynamics. *Front Mol Biosci* 9:834857. <https://doi.org/10.3389/fmolb.2022.834857>
- Pandey S (2010) Hybridoma technology for production of monoclonal antibodies. *Int J Pharm Sci Res* 1:88–94
- Pardridge WM (2022) Kinetics of blood-brain barrier transport of monoclonal antibodies targeting the insulin receptor and the transferrin receptor. *Pharmaceuticals* 15:3. <https://doi.org/10.3390/ph15010003>
- Peen E, Almer S, Bodemar G et al (1993) Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. *Gut* 34:56–62. <https://doi.org/10.1136/gut.34.1.56>
- Prieto-Fernández E, Egea-Mendikute L, Vila-Vecilla L et al (2021) Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2, neuropilin-1, syndecan-1 and cellular heparan sulfate. *Emerg Microbes Infect* 10:1065–1076. <https://doi.org/10.1080/22221751.2021.1932607>
- Prokofyev A, Gershovich P, Strelkova A, et al (2021) AAV5-based vaccine for induction of specific immunity to SARS-CoV-2 virus and/or prevention of SARS-CoV-2-induced coronavirus infection. Patent RU 2761879 C1 Published 13.12.2021
- Pulina MO, Zakharova ET, Sokolov AV et al (2002) Studies of the ceruloplasmin-lactoferrin complex. *Biochem Cell Biol* 80:35–39. <https://doi.org/10.1139/c01-206>
- Pulina MO, Sokolov AV, Zakharova ET et al (2010) Effect of lactoferrin on consequences of acute experimental hemorrhagic anemia in rats. *Bull Exp Biol Med* 149:219–222. <https://doi.org/10.1007/s10517-010-0911-6>
- Rawat P, Kumar S, Sheokand N et al (2012) The multifunctional glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a novel macrophage lactoferrin receptor. *Biochem Cell Biol* 90:329–338. <https://doi.org/10.1139/o11-058>
- Römer M, Eichner J, Metzger U et al (2014) Cross-platform toxicogenomics for the prediction of non-genotoxic hepatocarcinogenesis in rat. *PLoS ONE* 9:e97640. <https://doi.org/10.1371/journal.pone.0097640>
- Rosa L, Cutone A, Lepanto MS et al (2017) Lactoferrin: a natural glycoprotein involved in iron and inflammatory homeostasis. *Int J Mol Sci* 18:1985. <https://doi.org/10.3390/ijms18091985>
- Sabatucci A, Angelucci CB, Maccarrone M et al (2007) Structural characterization of the ceruloplasmin: lactoferrin complex in solution. *J Mol Biol* 371:1038–1046. <https://doi.org/10.1016/j.jmb.2007.05.089>
- Sakamoto K, Ito Y, Mori T, Sugimura K (2006) Interaction of human lactoferrin with cell adhesion molecules through RGD motif elucidated by lactoferrin-binding epitopes. *J Biol Chem* 281:24472–24478. <https://doi.org/10.1074/jbc.M604974200>
- Sakamoto S, Kawabata H, Masuda T et al (2015) H-ferritin is preferentially incorporated by human erythroid cells through transferrin receptor 1 in a threshold-dependent manner. *PLoS ONE* 10:e0139915. <https://doi.org/10.1371/journal.pone.0139915>
- Salaris C, Scarpa M, Elli M et al (2021) Protective effects of lactoferrin against SARS-CoV-2 infection in vitro. *Nutrients* 13:328. <https://doi.org/10.3390/nu13020328>
- Samygina VR, Sokolov AV, Bourenkov G et al (2013) Ceruloplasmin: macromolecular assemblies with iron-containing acute phase proteins. *PLoS ONE* 8:e67145. <https://doi.org/10.1371/journal.pone.0067145>
- Scialo F, Daniele A, Amato F et al (2020) ACE2: the major cell entry receptor for SARS-CoV-2. *Lung* 198:867–877. <https://doi.org/10.1007/s00408-020-00408-4>
- Seligman PA, Allen RH (1987) Isolation of transferrin receptor from human placenta. *Methods Enzymol* 147:239–247. [https://doi.org/10.1016/0076-6879\(87\)47114-0](https://doi.org/10.1016/0076-6879(87)47114-0)

- Semak I, Budzevich A, Maliushkova E et al (2019) Development of dairy herd of transgenic goats as biofactory for large-scale production of biologically active recombinant human lactoferrin. *Transgenic Res* 28:465–478. <https://doi.org/10.1007/s11248-019-00165-y>
- Shang J, Ye G, Shi K et al (2020) Structural basis of receptor recognition by SARS-CoV-2. *Nature* 581:221–224. <https://doi.org/10.1038/s41586-020-2179-y>
- Shida H, Nakazawa D, Tateyama Y et al (2016) The presence of anti-lactoferrin antibodies in a subgroup of eosinophilic granulomatosis with polyangiitis patients and their possible contribution to enhancement of neutrophil extracellular trap formation. *Front Immunol* 7:636. <https://doi.org/10.3389/fimmu.2016.00636>
- Sokolov AV, Pulina MO, Zakharova ET et al (2006) Identification and isolation from breast milk of ceruloplasmin-lactoferrin complex. *Biochemistry* 71:160–166. <https://doi.org/10.1134/s0006297906020076>
- Sokolov AV, Voynova IV, Kostevich VA et al (2017) Comparison of Interaction between Ceruloplasmin and Lactoferrin/Transferrin: to Bind or Not to Bind. *Biochemistry (Mosc)*. 82:1073–1078. <https://doi.org/10.1134/S0006297917090115>
- Sokolov A, Isakova-Sivak I, Grudinina N et al (2022a) Ferristatin II efficiently inhibits SARS-CoV-2 replication in vero cells. *Viruses* 14:317. <https://doi.org/10.3390/v14020317>
- Sokolov AV, Dubrovskaya NM, Kostevich VA et al (2022b) Lactoferrin induces erythropoietin synthesis and rescues cognitive functions in the offspring of rats subjected to prenatal hypoxia. *Nutrients* 14:1399. <https://doi.org/10.3390/nu14071399>
- Suriawinata E, Mehta KJ (2022) Iron and iron-related proteins in COVID-19. *Clin Exp Med* 2022:1–23. <https://doi.org/10.1007/s10238-022-00851-y>
- Suzuki YA, Lopez V, Lönnerdal B (2005) Mammalian lactoferrin receptors: structure and function. *Cell Mol Life Sci* 62:2560–2575. <https://doi.org/10.1007/s00018-005-5371-1>
- Tan L, Zhang Y, Peng W et al (2014) Detection of anti-lactoferrin antibodies and anti-myeloperoxidase antibodies in autoimmune hepatitis: a retrospective study. *J Immunoassay Immunochem* 35:388–397. <https://doi.org/10.1080/15321819.2013.879450>
- Tang X, Yang M, Duan Z et al (2020a) Transferrin receptor is another receptor for SARS-CoV-2 entry. *BioRxiv*. <https://doi.org/10.1101/2020a.10.23.350348>
- Tang X, Zhang Z, Fang M et al (2020b) Transferrin plays a central role in coagulation balance by interacting with clotting factors. *Cell Res* 30:119–132. <https://doi.org/10.1038/s41422-019-0260-6>
- Turkewitz AP, Amatruda JF, Borhani D et al (1988) A high yield purification of the human transferrin receptor and properties of its major extracellular fragment. *J Biol Chem* 263:8318–8325
- Wang K, Chen W, Zhang Z et al (2020a) CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. *Sig Transduct Target Ther* 5:283. <https://doi.org/10.1038/s41392-020-00426-x>
- Wang M, Cao R, Zhang L et al (2020b) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 30:269–271. <https://doi.org/10.1038/s41422-020-0282-0>
- Wang S, Qiu Z, Hou Y et al (2021) AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. *Cell Res* 31:126–140. <https://doi.org/10.1038/s41422-020-00460-y>
- Ward JL, Torres-Gonzalez M, Ammons MCB (2022) The influence of viral infections on iron homeostasis and the potential for lactoferrin as a therapeutic in the age of the SARS-CoV-2 pandemic. *Nutrients* 14:3090. <https://doi.org/10.3390/nu14153090>
- Wei C, Wan L, Yan Q et al (2020) HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. *Nat Metab* 2:1391–1400. <https://doi.org/10.1038/s42255-020-00324-0>
- Westerhausen M, Meuret G (1977) Transferrin-immune complex disease. *Acta Haematol* 57:96–101. <https://doi.org/10.1159/000207865>
- Wotring JW, Fursmidt R, Ward L, Sexton JZ (2022) Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern. *J Dairy Sci* 105:2791–2802. <https://doi.org/10.3168/jds.2021-21247>
- Xu G, Liu R, Zak O, Aisen P, Chance MR (2005) Structural allostery and binding of the transferrin\*receptor complex. *Mol Cell Proteomics* 4:1959–1967. <https://doi.org/10.1074/mcp.M500095-MCP200>
- Zakharova ET, Kostevich VA, Sokolov AV, Vasilyev VB (2012) Human apo-lactoferrin as a physiological mimetic of hypoxia stabilizes hypoxia-inducible factor-1 alpha. *Biometals* 25:1247–1259. <https://doi.org/10.1007/s10534-012-9586-y>
- Zakharova ET, Sokolov AV, Pavlichenko NN et al (2018) Erythropoietin and Nrf2: key factors in the neuroprotection provided by apo-lactoferrin. *Biometals* 31:425–443. <https://doi.org/10.1007/s10534-018-0111-9>
- Zhang Q, Chen CZ, Swaroop M et al (2020) Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. *Cell Discov* 6:80. <https://doi.org/10.1038/s41421-020-00222-5>
- Zhang Z, Lu M, Chen C et al (2021) Holo-lactoferrin: the link between ferroptosis and radiotherapy in triple-negative breast cancer. *Theranostics* 11:3167–3182. <https://doi.org/10.7150/thno.52028>
- Zhang H, Jin C, Zhang L et al (2022) CD71-specific aptamer conjugated with monomethyl auristatin E for the treatment of uveal melanoma. *ACS Appl Mater Interfaces* 14:32–40. <https://doi.org/10.1021/acsami.1c13980>
- Zhou C, Chen Y, Ji Y et al (2020) Increased serum levels of hepcidin and ferritin are associated with severity of COVID-19. *Med Sci Monit* 26:e926178. <https://doi.org/10.12659/MSM.926178>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.